Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(10bR)-8-chloro-4,10b-dimethyl-1,4,6,10b-tetrahydrobenzo[f]quinoline-3(2H)-thione
13.2% inhibition at 0.04 mM
(10bR)-8-chloro-4,10b-dimethyl-1,5,6,10b-tetrahydrophenanthridin-3(2H)-one
-
(10bR)-8-chloro-4,5,10b-trimethyl-1,5,6,10b-tetrahydrophenanthridin-3(2H)-one
-
(10bR)-8-chloro-5,10b-dimethyl-1,5,6,10b-tetrahydrophenanthridin-3(2H)-one
-
(11aR)-7-(1-hydroxypropan-2-yl)-1,4a,6a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
weak inhibition
(11aR)-7-(1-hydroxypropan-2-yl)-1,4a,6a-trimethyltetradecahydrocyclopenta[5,6]naphtho[2,1-d][1,3]oxazin-2(1H)-one
weak inhibition
(11aR)-7-(1-hydroxypropan-2-yl)-1,4a,6a-trimethyltetradecahydrocyclopenta[5,6]naphtho[2,1-d][1,3]oxazine-2(1H)-thione
weak inhibition
(11aR)-N,N-diethyl-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
weak inhibition
(16alpha,17beta)-17-hydroxy-16-methylandrost-4-en-3-one
-
(16beta)-16-bromo-3,20-dioxopregna-1,4,6-trien-17-yl cyclopentylacetate
-
(16beta)-16-methyl-3,20-dioxopregna-1,4,6-trien-17-yl acetate
-
(16beta)-16-methyl-3,20-dioxopregna-1,4,6-trien-17-yl cyclopentylacetate
-
(16beta)-16-methyl-3,20-dioxopregna-1,4,6-trien-17-yl pentanoate
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl cyclopentylacetate
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl cyclopropanecarboxylate
-
(16beta)-16-methylandrost-4-ene-3,17-dione
-
(16beta)-17-hydroxy-16-methylpregna-1,4,6-triene-3,20-dione
-
(16beta)-6-bromo-16-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate
-
(16beta)-6-bromo-17-(hex-1-en-2-yloxy)-16-methylpregna-4,6-diene-3,20-dione
-
(16beta)-6-chloro-16-methyl-17-[(1-phenylethenyl)oxy]pregna-4,6-diene-3,20-dione
-
(16beta)-6-chloro-16-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate
-
(17beta)-16-ethyl-17-hydroxyandrost-4-en-3-one
-
(17beta)-17-(2-oxo-3-phenyl-1,3-oxazinan-6-yl)androst-4-en-3-one - 3-phenyl-1,3-oxazinan-2-one (1:1)
-
(17beta)-17-(propan-2-ylcarbamoyl)estra-1(10),2,4,6,8-pentaene-3-carboxylic acid
-
(17beta)-17-(propan-2-ylcarbamoyl)estra-1(10),2,4,6-tetraene-3-carboxylic acid
-
(17beta)-17-(propan-2-ylcarbamoyl)estra-1(10),2,4-triene-3-carboxylic acid
-
(17beta)-17-(propan-2-ylcarbamoyl)estra-1,3,5(10)-triene-3-sulfonic acid
-
(17beta)-17-[3-(4-bromophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
(17beta)-17-[3-(4-chlorophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
(17beta)-17-[3-(4-ethoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
(17beta)-17-[3-(4-ethylphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
(17beta)-17-[3-(4-methoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
(17beta)-17-[di(propan-2-yl)carbamoyl]-4-fluoroandrost-3-ene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]-4-methylandrosta-3,5-diene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]-6-fluoroandrosta-3,5-diene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]androst-3-ene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-2,4,6-triene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-3,5,11-triene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-3,5-diene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]estra-3,5-diene-3-carboxylic acid
-
(17beta)-2-chloro-17-(propan-2-ylcarbamoyl)estra-1(10),2,4-triene-3-carboxylic acid
-
(17beta)-3-(hydroxymethyl)-N-(propan-2-yl)androsta-3,5-diene-17-carboxamide
weak inhibitor
(17beta)-3-nitro-N-(propan-2-yl)androst-3-ene-17-carboxamide
-
(17beta)-4-bromo-N-tert-butyl-3-oxoandrost-4-ene-17-carboxamide
-
(17beta)-4-fluoro-17-(propan-2-ylcarbamoyl)estra-1(10),2,4-triene-3-carboxylic acid
-
(17beta)-N-tert-butyl-3-oxo-4-sulfanylandrost-4-ene-17-carboxamide
-
(17beta)-N-tert-butyl-4-chloro-3-oxoandrost-4-ene-17-carboxamide
-
(17beta)-N-tert-butyl-4-cyano-3-oxoandrost-4-ene-17-carboxamide
-
(1R,4R,9aR,11aR)-4,9a,11a-trimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
-
(1R,4S,9aR,11aR)-4,9a,11a-trimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
-
(1R,9aR,11aR)-9a,11a-dimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
-
(1S,8bS,10aS)-N,N-diethyl-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,7,7a,8,8a,8b,8c,9,10,10a-hexadecahydrocyclopenta[i]cyclopropa[a]phenanthridine-1-carboxamide
-
(1S,9aR,11aR)-1-butyl-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
-
(1S,9aR,11aS)-1-(cyclohexylacetyl)-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
-
(1S,9aR,11aS)-6-bromo-9a,11a-dimethyl-7-oxo-N-(tricyclo[3.3.1.13,7]dec-1-yl)-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-6-bromo-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-6-chloro-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-6-chloro-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-9a,11a-dimethyl-1-nonanoyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
-
(1S,9aR,11aS)-9a,11a-dimethyl-N-(2-methylpropyl)-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N,N-diethyl-5,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N,N-diethyl-5,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N,N-diethyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-(4,4'-di-tert-butylbiphenyl-3-yl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-(4-tert-butylbiphenyl-3-yl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-(5-bromo-2-tert-butylphenyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-(dicyclohexylmethyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-(diphenylmethyl)-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-(diphenylmethyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-tert-butyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-[1-(4-chlorophenyl)cyclobutyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-[2-tert-butyl-5-(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-[bis(4-chlorophenyl)methyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aS,11aS)-N,N-diethyl-8,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(20E)-20-(hydroxyimino)pregn-4-en-3-one
-
(20E)-20-(hydroxyimino)pregn-4-ene-3,6-dione
-
(20E)-20-(hydroxyimino)pregna-4,14,16-trien-3-one
-
(20E)-20-(hydroxyimino)pregna-4,16-dien-3-one
-
(21E)-21-(hydroxyimino)pregn-4-en-3-one
-
(22R,S)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
i.e. FCE 28260
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,10a,10b,11,12,12a-dodecahydrochrysen-2-yl acetate
-
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (2-fluorophenyl)acetate
-
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl acetate
-
(2R,3R,10aR,12aS)-2-hydroxy-2,10a,12a-trimethyl-3-phenyl-3,4,4a,10a,10b,11,12,12a-octahydrochrysene-1,8(2H,4bH)-dione
-
(2R,3R,10aR,12aS)-2-hydroxy-2,10a,12a-trimethyl-3-phenyl-3,4,4a,9,10,10a,10b,11,12,12a-decahydrochrysene-1,8(2H,4bH)-dione
-
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-bromopropanoate
-
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-chloropropanoate
-
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-iodopropanoate
-
(3beta)-6,20-dioxopregna-4,16-dien-3-yl propanoate
-
(3E,4aR,6aS,7S,11aR)-N,N-diethyl-3-(hydroxymethylidene)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]-3-fluorophenyl)acetic acid
-
(4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]phenyl)acetic acid
-
(4aR,10bR)-4,10b-dimethyl-8-[(E)-2-phenylethenyl]-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-4,8-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-8-(furan-2-yl)-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-8-bromo-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-8-chloro-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-8-chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-8-chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinoline-3(2H)-thione
21.6% inhibition at 0.04 mM
(4aR,10bR)-8-chloro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
i.e. LY191704
(4aR,10bR)-8-fluoro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-8-[(E)-2-(isoquinolin-4-yl)ethenyl]-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-4a,6a,10-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aR)-1,4a,6a,10-tetramethyl-7-(6-methylheptan-2-yl)-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aR)-1,4a,6a,10-tetramethyl-7-(6-methylheptan-2-yl)-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aR)-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)-10-propyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aR)-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)hexadecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aR)-10-ethyl-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)hexadecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aR)-4a,6a,10-trimethyl-7-(6-methylheptan-2-yl)-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-2-oxo-N-(4,4,4-trifluoro-2-methyl-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-2-oxo-N-(4,4,4-trifluoro-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-N-(2-methyl-4-oxopentan-3-yl)-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,11aR)-N-(2-cyanopropan-2-yl)-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7E,11aR)-7-(chloromethylidene)-1,6a-dimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
i.e. azaestranone II
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-phenylhexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-[2-(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-4a,6a-dimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-4a,6a-dimethyl-2,5-dioxo-N-phenylhexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-N,1,4a,6a-tetramethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-N,4a,6a-trimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-N-(2-chlorophenyl)-1,4a,6a-trimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-N-[2,5-bis(trifluoromethyl)phenyl]-1,4a,6a-trimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-2-oxo-N-(4,4,4-trifluoro-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-4,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]isoquinolin-7-ol 2-oxide
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-7-hydroxy-1,4a,6a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aS,7S,11aR)-N-(3,3-dimethylpentanoyl)-1,4a,6a-trimethyl-N-(2-methylbutan-2-yl)-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-1,4a,6a-trimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-N-cyclohexyl-N-(cyclohexylacetyl)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-N-[2,5-bis(trifluoromethyl)phenyl]-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,7S)-8-ethyl-4a,7-dimethyl-10-methylidene-7-[(2S)-3-oxobutan-2-yl]-4,4a,4b,5,6,7,8,8a,9,10-decahydrophenanthren-2(3H)-one
-
(4aS,6aS,7S,11aR)-4a,6a-dimethyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[5,4-f]isoquinolin-7-ol
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N,N-diphenyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N-phenyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N-[2-(trifluoromethyl)phenyl]-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-4,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinolin-7-ol 3-oxide
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-7-[methyl(phenyl)carbamoyl]-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinolinium
-
(4aS,6aS,7S,11aS)-N,N-di(1H-indol-1-yl)-4a,6a-dimethyl-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
-
(4aS,6aS,7S,11aS)-N-(biphenyl-3-yl)-4a,6a-dimethyl-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
-
(4R)-5,10-seco-19-nor-pregna-4,5-diene-3,10,20-trione
a non-competitive and possibly irreversible inhibitor
(4R)-5,10-seco-estra-4,5-diene-3,10,17-trione
a non-competitive and possibly irreversible inhibitor
(5,20R)-4-diazo-21-hydroxy-20-methyl-pregn-6-en-3-one
i.e. RMI-18,341
(5alpha,6alpha)-20-oxo-5,6-epoxypregn-16-en-3-yl acetate
-
(5alpha17beta)-17-N,N-diethylcarbamoyl-4-methyl-4-aza-5-androstan-3-one
-
(5aR,7aS,8S,12aR)-5a,7a-dimethyl-2-oxooctadecahydrocyclopenta[5,6]naphtho[2,1-b]azepin-8-yl acetate
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethyl-1,2,3,3a,3b,4,5,5a,6,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethylhexadecahydro-7H-indolo[5,4-f]quinolin-7-one
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-9a,11a-dimethyl-1,2,3,3a,3b,4,5,5a,6,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-9a,11a-dimethylhexadecahydro-7H-indolo[5,4-f]quinolin-7-one
-
(6aR,7S,9aR,11aS)-7-hydroxy-1,9a,11a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(6aS,10aS,12aS)-1,10a,12a-trimethylhexadecahydronaphtho[2,1-f]quinoline-2,8-dione
-
(6aS,7S)-6a-methyl-N-(propan-2-yl)-5,6,6a,7,8,9,9a,9b-octahydro-4bH-indeno[5,4-f]isoquinoline-7-carboxamide 2-oxide
-
(6aS,7S)-N,N-diethyl-6a-methyl-5,6,6a,7,8,9,9a,9b-octahydro-4bH-indeno[5,4-f]isoquinoline-7-carboxamide 2-oxide
-
(6aS,8S,10aS,12aS)-8-hydroxy-1,10a,12a-trimethylhexadecahydronaphtho[2,1-f]quinolin-2(1H)-one
-
(6beta)-6-bromo-16-methyl-17-[(1-phenylethenyl)oxy]pregna-4,6-diene-3,20-dione
-
(7-chloro-3,4,4a,9-tetrahydrophenanthren-2-yl)phosphinic acid
-
(7aR,9aS,10S)-N,N-diethyl-7a,9a-dimethyl-5-oxo-1,2,3,5,6,7,7a,7b,8,9,9a,10,11,12,12a,12b-hexadecahydrobenzo[b]indeno[5,4-d]azepine-10-carboxamide
-
(7aS,8S,10aS,10bS)-N-tert-butyl-7a-methyl-2-oxo-2,3,4,5a,6,7,7a,8,9,10,10a,10b,11,12-tetradecahydrocyclopenta[f]pyrido[1,2-a]quinoline-8-carboxamide
-
(7aS,8S,12aR)-7a-methyl-8-(phenylamino)-5a,6,7,7a,8,9,10,10a,10b,11,12,12a-dodecahydrocyclopenta[f]pyrido[1,2-a]quinolin-2(1H)-one
-
(7aS,8S,12aR)-8-[benzyl(phenyl)amino]-7a-methyl-5a,6,7,7a,8,9,10,10a,10b,11,12,12a-dodecahydrocyclopenta[f]pyrido[1,2-a]quinolin-2(1H)-one
-
(8a,9b,10x,14x)-N-tert-butyl-3-oxoestr-4-ene-17-carboxamide
-
(8R,9aS,11aS)-1,9a,11a-trimethyl-2-oxo-N,N-di(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-8-carboxamide
-
(9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethyl-1,2,3,3a,3b,4,6,8,9,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
-
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]-butyric acid
-
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]butyric acid
-
1-(3-carboxypropyl)-4-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrole-3-carboxylic acid
-
1-cyclopropyl-3-ethyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
20% inhibition at 100 nM in transfected SW-13 cells
1-cyclopropyl-3-methyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
-
1-cyclopropyl-3-phenyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
-
1-cyclopropyl-3-phenyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
1-methyl-5-phenylpiperidin-2-one
13.5% inhibition at 0.04 mM
1-methyl-5-[4-[(E)-2-phenylethenyl]phenyl]piperidin-2-one
-
1-methyl-5-[4-[(E)-phenyldiazenyl]phenyl]piperidin-2-one
-
16,16-dimethylandrost-4-ene-3,17-dione
-
16-ethyl-17beta-hydroxy-4-estren-3-one
i.e. TSAA-291
17-(2-cyclopentylethoxy)-6-methylidenepregn-4-ene-3,20-dione
-
17-(3-cyclopentylpropoxy)-6-methylidenepregn-4-ene-3,20-dione
-
17-hydroxy-6-methylidenepregn-4-ene-3,20-dione
-
17-hydroxyestra-4,8-dien-3-one
-
17-hydroxyestra-4,9(11)-dien-3-one
-
17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one
-
17beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5alpha-androstan-3-one
-
17beta-N-(2,5-bis(trifluoromethyl)-phenyl)-3-oxo-4-aza-5alpha-androst-1-ene-17-carboxamide
-
2',3'-tetrahydrofuran-2'-spiro-17-(6-methylene-4-androsten-3-one)
i.e. L612,710
2-(trifluoromethyl)phenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
368% inhibition at 0.01 mM
2-fluorophenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
166% inhibition at 0.01 mM
2-methyl-N-phenyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]propanamide
-
2-oxo-8-(prop-2-en-1-yl)-2H-chromen-7-yl benzoate
-
20-oxo-16,17-epoxypregn-5-en-3-yl acetate
-
3,20-dioxopregn-4-en-17-yl (4-bromophenyl)carbamate
-
3,20-dioxopregn-4-en-17-yl phenylcarbamate
-
3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
-
3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
-
3,20-dioxopregna-4,6-dien-17-yl benzoate
-
3-(2,4-dimethoxyphenyl)-5-methoxy-8,8-dimethyl-4H,8H-pyrano[2,3-f]chromen-4-one
-
3-butyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
4.9% inhibition at 100 nM in transfected SW-13 cells
3-butyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
46.3% inhibition at 100 nM in transfected SW-13 cells
3-chloro-4-(4-[N-(4-phenoxybenzyl)amino]phenoxy)benzoic acid
-
3-chloro-4-([1-(4-methoxybenzyl)-2,3-dihydro-1H-indol-5-yl]oxy)benzoic acid
-
3-chloro-4-([1-(4-phenoxybenzoyl)-1H-indol-5-yl]oxy)benzoic acid
-
3-chloro-4-([1-(4-phenoxybenzyl)indolin-5-yl]oxy)benzoic acid
i.e. YM-36117
3-chloro-4-([1-(furan-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]oxy)benzoic acid
-
3-cyclohexyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
-
3-cyclohexyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
48.7% inhibition at 100 nM in transfected SW-13 cells
3-fluorophenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
134% inhibition at 0.01 mM
3-hydroxy-16,17-epoxypregn-5-en-20-one
-
3-[2,4-bis(benzyloxy)phenyl]-5-methoxy-8,8-dimethyl-4H,8H-pyrano[2,3-f]chromen-4-one
-
3-[2,4-bis(benzyloxy)phenyl]-5-methoxy-8,8-dimethyl-8,9-dihydro-4H,10H-pyrano[2,3-f]chromene-4,10-dione
-
4'-(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)biphenyl-4-carboxylic acid
-
4'-[2-[di(propan-2-yl)amino]-2-oxoethoxy]-3',5'-di(propan-2-yl)biphenyl-4-carboxylic acid
-
4'-[2-[di(propan-2-yl)amino]-2-oxoethoxy]-3'-fluoro-5'-nitrobiphenyl-4-carboxylic acid
-
4-(1-benzyl-1H-indol-5-yl)benzoic acid
-
4-(2-[1-(4,4'-dipropylbenzhydryl)indole-5-carboxamido]phenoxy)butyric acid
-
4-(2-[[(2E)-3-[1-[bis(4-fluorophenyl)methyl]-1H-indol-5-yl]pent-2-enoyl]amino]phenoxy)butanoic acid
i.e. KF20405
4-(3-(4-(N-methylacetamido)phenyl) pentan-3-yl) phenyldibenzylcarbamate
-
4-(3-[[2,2-bis(4-chlorophenyl)-1,3-benzodioxol-5-yl]carbonyl]-2-methyl-1H-indol-1-yl)butanoic acid
-
4-(4-benzoylphenoxy)benzoic acid
-
4-(biphenyl-4-yloxy)-2-chlorobenzoic acid
-
4-(biphenyl-4-yloxy)-2-fluorobenzoic acid
-
4-(biphenyl-4-yloxy)-3-methoxybenzoic acid
-
4-(methoxycarbonyl)phenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
584% inhibition at 0.01 mM
4-bromo-3,20-dioxopregn-4-en-17-yl 4-chlorobenzoate
-
4-bromo-3,20-dioxopregn-4-en-17-yl 4-fluorobenzoate
-
4-bromo-3,20-dioxopregna-1,4-dien-17-yl acetate
-
4-fluorophenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
119% inhibition at 0.01 mM
4-methylphenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
553% inhibition at 0.01 mM
4-trifluoromethyl-N-(tert-butyl)-4-androsten-17beta-carboxamide
-
4-[(1-benzyl-1H-indol-5-yl)oxy]-3-chlorobenzoic acid
-
4-[1-(6,6-dimethyl-6H-dibenzo[b,d]pyran-3-yl)methylindol-3-yl]-butyric acid
i.e. FR119680
4-[2-(1-methyl-6-oxopiperidin-3-yl)ethyl]-N,N-di(propan-2-yl)benzamide
-
4-[2-(5-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
-
4-[2-(6-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
-
4-[3-(1-methyl-6-oxopiperidin-3-yl)butan-2-yl]-N,N-di(propan-2-yl)benzamide
-
4-[3-(4-[(1R)-1-[4-(2-methylpropyl)phenyl]ethoxy]benzoyl)-1H-indol-1-yl]butanoic acid
-
4-[3-([(2R)-2-methyl-2-[4-(2-methylpropyl)phenyl]-1,3-benzodioxol-5-yl]carbonyl)-1H-indol-1-yl]butanoic acid
-
4-[3-ethyl-4-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrol-1-yl]butanoic acid
-
4-[3-[3-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-4-(propan-2-yl)-1H-pyrrol-1-yl]butanoic acid
-
4-[3-[3-[bis (4-isobutylphenyl)methylamino]benzoyl]-lH-indol-l-yl] butyric acid
i.e. FK-143
4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]-lH-indol-l-yl]butyric acid
-
4-[3-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrol-1-yl]butanoic acid
-
4-[3-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-4-(propan-2-yl)-1H-pyrrol-1-yl]butanoic acid
-
4-[4-(4-methylbenzoyl)phenoxy]benzoic acid
-
4-[4-(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)phenoxy]benzoic acid
-
4-[4-[di(propan-2-yl)carbamoyl]-2-ethylphenyl]cyclohex-1-ene-1-carboxylic acid
-
4-[[1-(2-propylpentanoyl)piperidin-4-ylidene]methyl]benzoic acid
-
4-[[1-(biphenyl-4-ylcarbamoyl)piperidin-4-ylidene]methyl]benzoic acid
-
4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]-3-fluorobenzoic acid
-
4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]benzoic acid
-
4-[[1-(diphenylacetyl)piperidin-4-ylidene]methyl]benzoic acid
-
5-(2-ethyl-3-[3-[(4-hexylundecyl)amino]benzoyl]-1H-pyrrol-1-yl)pentanoate
-
5-(4-chlorophenyl)-1-methylpiperidin-2-one
-
5-(4-chlorophenyl)-1-methylpiperidine-2-thione
14% inhibition at 0.04 mM
5-(benzyloxy)-1H-indole-2-carboxylic acid
-
5-bromo-N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]pentanamide
-
6,20-dioxopregn-4-en-3-yl 4-bromobenzoate
-
6,20-dioxopregn-4-en-3-yl 4-fluorobenzoate
-
6,20-dioxopregn-4-en-3-yl 5-chloropentanoate
-
6,20-dioxopregna-4,16-dien-3-yl 4-bromobenzoate
-
6,20-dioxopregna-4,16-dien-3-yl 4-fluorobenzoate
-
6,20-dioxopregna-4,16-dien-3-yl 4-methylbenzoate
-
6,20-dioxopregna-4,16-dien-3-yl acetate
-
6,20-dioxopregna-4,16-dien-3-yl benzoate
-
6-(benzyloxy)-5-methoxy-1-methyl-1H-indole-2-carboxylic acid
-
6-([5-[(1R,4aR,6aR,7R,11aR)-1,4a,6a-trimethyl-1-oxidohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]hexanoyl]amino)hexanoic acid
-
6-([5-[(1S,4aR,6aR,7R,11aR)-1,4a,6a-trimethyl-1-oxidohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]hexanoyl]amino)hexanoic acid
-
6-bromo-3,20-dioxopregna-4,6-dien-17-yl acetate
i.e. ONO-3806
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl benzoate
-
6-hydroxy-9,10-dimethoxy-3,3-dimethyl-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(13H)-one
-
6-methylidene-3,20-dioxopregn-4-en-17-yl 4-bromobenzoate
-
6-[(1R,4aR,6aR,7R,11aR)-7-[6-[(4-cyanobenzyl)oxy]hexan-2-yl]-4a,6a-dimethyl-1-oxidohexadecahydro-1H-indeno[5,4-f]quinolin-1-yl]hexanoic acid
-
6-[(1S,4aR,6aR,7R,11aR)-7-[6-[(4-cyanobenzyl)oxy]hexan-2-yl]-4a,6a-dimethyl-1-oxidohexadecahydro-1H-indeno[5,4-f]quinolin-1-yl]hexanoic acid
-
6-[3-(N,N-dicyclohexylaminocarbonyl)phenyl]-3,4-dihydro-naphthalene-2-carboxylic acid
-
6-[4-(N,N-diisopropylamino-carbonyl)phenyl]naphthalene-2-carboxylic acid
6-[4-(N,N-diisopropylcarbamoyl) phenyl]-1H-quinolin-2-one
competitive inhibitor
6-[4-(N,N-diisopropylcarbamoyl) phenyl]-N-methyl-quinolin-2-one
-
6-[4-[di(propan-2-yl)carbamoyl]phenyl]-3,4-dihydronaphthalene-2-carboxylic acid
-
7-bromo-9,10-dihydrophenanthrene-2-carboxylic acid
-
7-chloro-3,4,4a,9-tetrahydrophenanthrene-2-carboxylic acid
-
7-chloro-9,10-dihydrophenanthrene-2-carboxylic acid
-
7-[(3-methylbut-2-en-1-yl)oxy]-2H-chromen-2-one
-
7-[(E)-2-phenylethenyl]-9,10-dihydrophenanthrene-2-carboxylic acid
-
9,10-dihydrophenanthrene-2-carboxylic acid
-
androst-4-ene-3,17-dione
-
catechin
from green tea, Camellia sinensis, is specific for SRD5alpha1 inhibition
estra-4,8-diene-3,17-dione
-
estra-4,9(11)-diene-3,17-dione
-
ethyl 4-[2-[([1-[bis(4-propylphenyl)methyl]-1H-benzimidazol-5-yl]carbonyl)amino]phenoxy]butanoate
-
gamma-linolenic acid
a natural product found in oil of evening primrose, Oenothera biennis, oil and borage, Borago officinalis, inhibits SRD5alpha1 and SRD5alpha2
methyl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
-
N,N-dicyclohexyl-4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzamide
-
N-(1,1,1,3,3,3-hexafluorophenylpropyl)-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
i.e. PNU 157706
N-(3,3-dimethylbutyl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-(3-methylbutan-2-yl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-(3-methylbutyl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-(4-methoxycyclohexyl)-2-methyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]propanamide
-
N-(dicyclohexyl)acetyl-piperidine-4-(benzylidene-4-carboxylic acid)
-
N-butyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-cyclohexyl-N-iodo-4-(2-methoxyquinolin-6-yl)benzamide
-
N-heptyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-iodo-4-(2-methoxyquinolin-6-yl)benzamide
-
N-octyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]butanamide
-
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-phenyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]benzamide
-
N-propyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-propyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-tert-butyl-3-oxoestra-4,9(11)-diene-17-carboxamide
-
N-[1,1,1-trifluoro-2-oxobut-3-yl]-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
-
pregna-4,16-diene-3,6,20-trione
-
tricyclo[3.3.1.13,7]dec-2-yl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
-
[(17beta)-17-(propan-2-ylcarbamoyl)androsta-3,5-dien-3-yl]phosphinic acid
-
[(17beta)-17-(propan-2-ylcarbamoyl)androsta-3,5-dien-3-yl]phosphonic acid
-
[3-methyl-4-(4-phenoxybenzoyl)phenyl]acetic acid
-
[4-(4-phenoxybenzoyl)phenyl]acetic acid
-
[4-(biphenyl-4-yloxy)phenyl]acetic acid
-
[4-[4-(4-bromophenoxy)benzoyl]phenyl]acetic acid
-
(10bR)-8-chloro-4,10b-dimethyl-1,4,6,10b-tetrahydrobenzo[f]quinoline-3(2H)-thione
-
(10bR)-8-chloro-4,10b-dimethyl-1,5,6,10b-tetrahydrophenanthridin-3(2H)-one
-
(10bR)-8-chloro-4,5,10b-trimethyl-1,5,6,10b-tetrahydrophenanthridin-3(2H)-one
-
(10bR)-8-chloro-5,10b-dimethyl-1,5,6,10b-tetrahydrophenanthridin-3(2H)-one
-
(11aR)-7-(1-hydroxypropan-2-yl)-1,4a,6a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
weak inhibition
(11aR)-7-(1-hydroxypropan-2-yl)-1,4a,6a-trimethyltetradecahydrocyclopenta[5,6]naphtho[2,1-d][1,3]oxazin-2(1H)-one
weak inhibition
(11aR)-7-(1-hydroxypropan-2-yl)-1,4a,6a-trimethyltetradecahydrocyclopenta[5,6]naphtho[2,1-d][1,3]oxazine-2(1H)-thione
weak inhibition
(11aR)-N,N-diethyl-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
weak inhibition
(16alpha,17beta)-17-hydroxy-16-methylandrost-4-en-3-one
-
(16beta)-16-bromo-3,20-dioxopregna-1,4,6-trien-17-yl cyclopentylacetate
-
(16beta)-16-methyl-3,20-dioxopregna-1,4,6-trien-17-yl acetate
-
(16beta)-16-methyl-3,20-dioxopregna-1,4,6-trien-17-yl cyclopentylacetate
-
(16beta)-16-methyl-3,20-dioxopregna-1,4,6-trien-17-yl pentanoate
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate
-
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl butanoate
-
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl cyclopentylacetate
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl cyclopropanecarboxylate
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl pentanoate
-
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl phenylacetate
-
-
(16beta)-16-methylandrost-4-ene-3,17-dione
-
(16beta)-17-hydroxy-16-methylpregna-1,4,6-triene-3,20-dione
-
(16beta)-6-bromo-16-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate
-
(16beta)-6-bromo-17-(hex-1-en-2-yloxy)-16-methylpregna-4,6-diene-3,20-dione
-
(16beta)-6-chloro-16-methyl-17-[(1-phenylethenyl)oxy]pregna-4,6-diene-3,20-dione
-
(16beta)-6-chloro-16-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate
-
(17beta)-16-ethyl-17-hydroxyandrost-4-en-3-one
-
(17beta)-17-(2-oxo-3-phenyl-1,3-oxazinan-6-yl)androst-4-en-3-one
-
-
(17beta)-17-(2-oxo-3-phenyl-1,3-oxazinan-6-yl)androst-4-en-3-one - 3-phenyl-1,3-oxazinan-2-one (1:1)
-
(17beta)-17-(propan-2-ylcarbamoyl)estra-1(10),2,4,6,8-pentaene-3-carboxylic acid
-
(17beta)-17-(propan-2-ylcarbamoyl)estra-1(10),2,4,6-tetraene-3-carboxylic acid
-
(17beta)-17-(propan-2-ylcarbamoyl)estra-1(10),2,4-triene-3-carboxylic acid
-
(17beta)-17-(propan-2-ylcarbamoyl)estra-1,3,5(10)-triene-3-sulfonic acid
-
(17beta)-17-[3-(4-bromophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
(17beta)-17-[3-(4-chlorophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
(17beta)-17-[3-(4-ethoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
(17beta)-17-[3-(4-ethylphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
(17beta)-17-[3-(4-methoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
(17beta)-17-[di(propan-2-yl)carbamoyl]-4-fluoroandrost-3-ene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]-4-methylandrosta-3,5-diene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]-6-fluoroandrosta-3,5-diene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]androst-3-ene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-2,4,6-triene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-3,5,11-triene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-3,5-diene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]estra-3,5-diene-3-carboxylic acid
-
(17beta)-2-chloro-17-(propan-2-ylcarbamoyl)estra-1(10),2,4-triene-3-carboxylic acid
-
(17beta)-3-(hydroxymethyl)-N-(propan-2-yl)androsta-3,5-diene-17-carboxamide
weak inhibitor
(17beta)-3-nitro-N-(propan-2-yl)androst-3-ene-17-carboxamide
-
(17beta)-4-bromo-N-tert-butyl-3-oxoandrost-4-ene-17-carboxamide
-
(17beta)-4-fluoro-17-(propan-2-ylcarbamoyl)estra-1(10),2,4-triene-3-carboxylic acid
-
(17beta)-N-tert-butyl-3-oxo-4-sulfanylandrost-4-ene-17-carboxamide
-
(17beta)-N-tert-butyl-4-chloro-3-oxoandrost-4-ene-17-carboxamide
-
(17beta)-N-tert-butyl-4-cyano-3-oxoandrost-4-ene-17-carboxamide
-
(1R,4R,9aR,11aR)-4,9a,11a-trimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
-
(1R,4S,9aR,11aR)-4,9a,11a-trimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
-
(1R,9aR,11aR)-9a,11a-dimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
-
(1S,8bS,10aS)-N,N-diethyl-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,7,7a,8,8a,8b,8c,9,10,10a-hexadecahydrocyclopenta[i]cyclopropa[a]phenanthridine-1-carboxamide
-
(1S,9aR,11aR)-1-butyl-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
-
(1S,9aR,11aS)-1-(cyclohexylacetyl)-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
-
(1S,9aR,11aS)-6-bromo-9a,11a-dimethyl-7-oxo-N-(tricyclo[3.3.1.13,7]dec-1-yl)-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-6-bromo-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-6-chloro-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-6-chloro-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-9a,11a-dimethyl-1-nonanoyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
-
(1S,9aR,11aS)-9a,11a-dimethyl-N-(2-methylpropyl)-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N,N-diethyl-5,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N,N-diethyl-5,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N,N-diethyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-(4,4'-di-tert-butylbiphenyl-3-yl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-(4-tert-butylbiphenyl-3-yl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-(5-bromo-2-tert-butylphenyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-(dicyclohexylmethyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-(diphenylmethyl)-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-(diphenylmethyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-tert-butyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-[1-(4-chlorophenyl)cyclobutyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-[2-tert-butyl-5-(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-[bis(4-chlorophenyl)methyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aS,11aS)-N,N-diethyl-8,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(20E)-20-(hydroxyimino)pregn-4-en-3-one
-
(20E)-20-(hydroxyimino)pregn-4-ene-3,6-dione
-
(20E)-20-(hydroxyimino)pregna-4,14,16-trien-3-one
-
(20E)-20-(hydroxyimino)pregna-4,16-dien-3-one
-
(21E)-21-(hydroxyimino)pregn-4-en-3-one
-
(22R,S)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
i.e. FCE 28260
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,10a,10b,11,12,12a-dodecahydrochrysen-2-yl acetate
-
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (2-fluorophenyl)acetate
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (3-fluorophenyl)acetate
-
-
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl acetate
-
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl phenylacetate
-
-
(2R,3R,10aR,12aS)-2-hydroxy-2,10a,12a-trimethyl-3-phenyl-3,4,4a,10a,10b,11,12,12a-octahydrochrysene-1,8(2H,4bH)-dione
-
(2R,3R,10aR,12aS)-2-hydroxy-2,10a,12a-trimethyl-3-phenyl-3,4,4a,9,10,10a,10b,11,12,12a-decahydrochrysene-1,8(2H,4bH)-dione
-
(2S,9aR,11aR)-2-(4-chlorophenoxy)-5,9a,11a-trimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
-
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-bromopropanoate
-
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-chloropropanoate
-
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-iodopropanoate
-
(3beta)-6,20-dioxopregna-4,16-dien-3-yl propanoate
-
(3E,4aR,6aS,7S,11aR)-N,N-diethyl-3-(hydroxymethylidene)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]-3-fluorophenyl)acetic acid
-
(4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]phenyl)acetic acid
-
(4alpha,5alpha)-3,20-dioxo-4,5-epoxypregnan-17-yl 4-bromobenzoate
-
-
(4alpha,5alpha)-3,20-dioxo-4,5-epoxypregnan-17-yl benzoate
-
-
(4aR,10bR)-4,10b-dimethyl-8-[(E)-2-phenylethenyl]-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-4,8-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-8-(furan-2-yl)-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-8-bromo-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-8-chloro-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-8-chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-8-chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinoline-3(2H)-thione
-
(4aR,10bR)-8-chloro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
i.e. LY191704
(4aR,10bR)-8-fluoro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-8-[(E)-2-(isoquinolin-4-yl)ethenyl]-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-4a,6a,10-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aR)-1,4a,6a,10-tetramethyl-7-(6-methylheptan-2-yl)-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aR)-1,4a,6a,10-tetramethyl-7-(6-methylheptan-2-yl)-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aR)-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)-10-propyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aR)-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)hexadecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aR)-10-ethyl-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)hexadecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aR)-4a,6a,10-trimethyl-7-(6-methylheptan-2-yl)-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-2-oxo-N-(4,4,4-trifluoro-2-methyl-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-2-oxo-N-(4,4,4-trifluoro-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-N-(2-methyl-4-oxopentan-3-yl)-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,11aR)-N-(2-cyanopropan-2-yl)-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7E,11aR)-7-(chloromethylidene)-1,6a-dimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
i.e. azaestranone II
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-phenylhexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-[2-(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-4a,6a-dimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-4a,6a-dimethyl-2,5-dioxo-N-phenylhexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-N,1,4a,6a-tetramethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-N,4a,6a-trimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-N-(2-chlorophenyl)-1,4a,6a-trimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-N-[2,5-bis(trifluoromethyl)phenyl]-1,4a,6a-trimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-2-oxo-N-(4,4,4-trifluoro-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-4,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]isoquinolin-7-ol 2-oxide
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-7-hydroxy-1,4a,6a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aS,7S,11aR)-N-(3,3-dimethylpentanoyl)-1,4a,6a-trimethyl-N-(2-methylbutan-2-yl)-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-1,4a,6a-trimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-N-cyclohexyl-N-(cyclohexylacetyl)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-N-[2,5-bis(trifluoromethyl)phenyl]-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,7S)-8-ethyl-4a,7-dimethyl-10-methylidene-7-[(2S)-3-oxobutan-2-yl]-4,4a,4b,5,6,7,8,8a,9,10-decahydrophenanthren-2(3H)-one
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N,N-diphenyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N-phenyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N-[2-(trifluoromethyl)phenyl]-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-4,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinolin-7-ol 3-oxide
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-7-[methyl(phenyl)carbamoyl]-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinolinium
-
(4aS,6aS,7S,11aS)-N,N-di(1H-indol-1-yl)-4a,6a-dimethyl-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
-
(4aS,6aS,7S,11aS)-N-(biphenyl-3-yl)-4a,6a-dimethyl-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
-
(4R)-5,10-seco-19-nor-pregna-4,5-diene-3,10,20-trione
a non-competitive and possibly irreversible inhibitor
(4R)-5,10-seco-estra-4,5-diene-3,10,17-trione
a non-competitive and possibly irreversible inhibitor
(5,20R)-4-diazo-21-hydroxy-20-methyl-pregn-6-en-3-one
i.e. RMI-18,341
(5alpha,6alpha)-20-oxo-5,6-epoxypregn-16-en-3-yl acetate
(5alpha17beta)-17-N,N-diethylcarbamoyl-4-methyl-4-aza-5-androstan-3-one
-
(5aR,7aS,8S,12aR)-5a,7a-dimethyl-2-oxooctadecahydrocyclopenta[5,6]naphtho[2,1-b]azepin-8-yl acetate
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethyl-1,2,3,3a,3b,4,5,5a,6,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethylhexadecahydro-7H-indolo[5,4-f]quinolin-7-one
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-9a,11a-dimethyl-1,2,3,3a,3b,4,5,5a,6,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-9a,11a-dimethylhexadecahydro-7H-indolo[5,4-f]quinolin-7-one
-
(6aR,7S,9aR,11aS)-7-hydroxy-1,9a,11a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(6aS,10aS,12aS)-1,10a,12a-trimethylhexadecahydronaphtho[2,1-f]quinoline-2,8-dione
-
(6aS,8S,10aS,12aS)-8-hydroxy-1,10a,12a-trimethylhexadecahydronaphtho[2,1-f]quinolin-2(1H)-one
-
(6beta)-6-bromo-16-methyl-17-[(1-phenylethenyl)oxy]pregna-4,6-diene-3,20-dione
-
(7-chloro-3,4,4a,9-tetrahydrophenanthren-2-yl)phosphinic acid
-
(7aR,9aS,10S)-N,N-diethyl-7a,9a-dimethyl-5-oxo-1,2,3,5,6,7,7a,7b,8,9,9a,10,11,12,12a,12b-hexadecahydrobenzo[b]indeno[5,4-d]azepine-10-carboxamide
-
(7aS,8S,12aR)-7a-methyl-8-(phenylamino)-5a,6,7,7a,8,9,10,10a,10b,11,12,12a-dodecahydrocyclopenta[f]pyrido[1,2-a]quinolin-2(1H)-one
-
(7aS,8S,12aR)-8-[benzyl(phenyl)amino]-7a-methyl-5a,6,7,7a,8,9,10,10a,10b,11,12,12a-dodecahydrocyclopenta[f]pyrido[1,2-a]quinolin-2(1H)-one
-
(8a,9b,10x,14x)-N-tert-butyl-3-oxoestr-4-ene-17-carboxamide
-
(8R,9aS,11aS)-1,9a,11a-trimethyl-2-oxo-N,N-di(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-8-carboxamide
-
(9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethyl-1,2,3,3a,3b,4,6,8,9,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
-
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]-butyric acid
-
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]butyric acid
-
1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
1,4,6-pregnatriene-3,20-dione
-
-
1-(3-carboxypropyl)-4-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrole-3-carboxylic acid
-
1-cyclopropyl-3-ethyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
-
1-cyclopropyl-3-methyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
-
1-cyclopropyl-3-phenyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
-
1-cyclopropyl-3-phenyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
-
1-methyl-5-phenylpiperidin-2-one
-
1-methyl-5-[4-(phenylacetyl)phenyl]pyridin-2(1H)-one
61% inhibition at 0.010 mM
1-methyl-5-[4-[(E)-2-phenylethenyl]phenyl]piperidin-2-one
-
1-methyl-5-[4-[(E)-phenyldiazenyl]phenyl]piperidin-2-one
-
16,16-dimethylandrost-4-ene-3,17-dione
-
16-ethyl-17beta-hydroxy-4-estren-3-one
i.e. TSAA-291
17-(2-cyclopentylethoxy)-6-methylidenepregn-4-ene-3,20-dione
-
17-(3-cyclopentylpropoxy)-6-methylidenepregn-4-ene-3,20-dione
-
17-hydroxy-6-methylidenepregn-4-ene-3,20-dione
-
17-hydroxyestra-4,8-dien-3-one
-
17-hydroxyestra-4,9(11)-dien-3-one
-
17-hydroxypregna-4,6-diene-3,20-dione
-
-
17beta-(N-tert-butyl carbamoyl)-19-nor-10-aza-4-androsten-3-one
-
17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one
-
17beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5alpha-androstan-3-one
-
17beta-N-(2,5-bis(trifluoromethyl)-phenyl)-3-oxo-4-aza-5alpha-androst-1-ene-17-carboxamide
-
1alpha,2alpha-epoxy-4,6-pregnadiene-3,20-dione
-
-
2',3'-tetrahydrofuran-2'-spiro-17-(6-methylene-4-androsten-3-one)
i.e. L612,710
2-(trifluoromethyl)phenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
42% inhibition at 0.010 mM
2-fluorophenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
138% inhibition at 0.010 mM
2-methyl-N-phenyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]propanamide
-
2-oxo-8-(prop-2-en-1-yl)-2H-chromen-7-yl benzoate
-
2-[4-(1,2-dimethyl-6-oxo-1,2,3,6-tetrahydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide
3% inhibition at 0.010 mM
2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(prop-2-en-1-yl)acetamide
6% inhibition at 0.010 mM
2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide
8% inhibition at 0.010 mM
2-[4-(1-methyl-6-oxopiperidin-3-yl)phenoxy]-N-(propan-2-yl)acetamide
6% inhibition at 0.010 mM
2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate
43% inhibition at 0.010 mM
20-hydroxyimino-1,4-pregnadiene-3-one
-
-
20-hydroxyimino-4-pregnene-3-one
-
-
20-hydroxyimino-5-oxo-A-nor-3,5-secopregnan-3-oic acid
-
-
20-oxo-16,17-epoxypregn-5-en-3-yl acetate
-
3,20-dioxopregn-4-en-17-yl (4-bromophenyl)carbamate
-
3,20-dioxopregn-4-en-17-yl phenylcarbamate
-
3,20-dioxopregna-4,6-dien-17-yl (4-bromophenyl)carbamate
-
-
3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
3,20-dioxopregna-4,6-dien-17-yl 4-chlorobenzoate
-
-
3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
3,20-dioxopregna-4,6-dien-17-yl benzoate
3,20-dioxopregna-4,6-dien-17-yl phenylcarbamate
-
-
3-(2,4-dimethoxyphenyl)-5-methoxy-8,8-dimethyl-4H,8H-pyrano[2,3-f]chromen-4-one
-
3-(2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethoxy)propyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate
33% inhibition at 0.010 mM
3-butyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
-
3-butyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
-
3-chloro-4-(4-[N-(4-phenoxybenzyl)amino]phenoxy)benzoic acid
-
3-chloro-4-([1-(4-phenoxybenzoyl)-1H-indol-5-yl]oxy)benzoic acid
-
3-chloro-4-([1-(4-phenoxybenzyl)indolin-5-yl]oxy)benzoic acid
i.e. YM-36117
3-chloro-4-([1-(furan-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]oxy)benzoic acid
-
3-chloro-4-[[1-(4-methoxybenzyl)-2,3-dihydro-1H-indol-5-yl]oxy]benzoic acid
-
3-cyclohexyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
-
3-cyclohexyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
-
3-fluorophenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
160% inhibition at 0.010 mM
3-hydroxy-16,17-epoxypregn-5-en-20-one
-
3-[2,4-bis(benzyloxy)phenyl]-5-methoxy-8,8-dimethyl-4H,8H-pyrano[2,3-f]chromen-4-one
-
3-[2,4-bis(benzyloxy)phenyl]-5-methoxy-8,8-dimethyl-8,9-dihydro-4H,10H-pyrano[2,3-f]chromene-4,10-dione
-
3-[4-(4-phenoxybenzoyl)phenyl]acrylic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.00047 mM, not inhibitory to isoform 1
3beta-acetoxy-20-hydroxyimino-5-pregnene
-
-
3beta-acetoxy-5-pregnen-20-one
-
-
3beta-hydroxy-20-hydroxyiminopregnenolone
-
-
4'-(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)biphenyl-4-carboxylic acid
-
4'-[2-[di(propan-2-yl)amino]-2-oxoethoxy]-3',5'-di(propan-2-yl)biphenyl-4-carboxylic acid
-
4'-[2-[di(propan-2-yl)amino]-2-oxoethoxy]-3'-fluoro-5'-nitrobiphenyl-4-carboxylic acid
-
4,4a,5,6,7,8,9,10-octahydro-3H-pyrido[1,2-a]quinolin-3-one
-
4,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
4-(1-benzyl-1H-indol-5-yl)benzoic acid
-
4-(2-[1-(4,4'-dipropylbenzhydryl)indole-5-carboxamido]phenoxy)butyric acid
-
4-(2-[[(2E)-3-[1-[bis(4-fluorophenyl)methyl]-1H-indol-5-yl]pent-2-enoyl]amino]phenoxy)butanoic acid
i.e. KF20405
4-(3-(4-(N-methylacetamido)phenyl) pentan-3-yl) phenyldibenzylcarbamate
-
4-(3-[[2,2-bis(4-chlorophenyl)-1,3-benzodioxol-5-yl]carbonyl]-2-methyl-1H-indol-1-yl)butanoic acid
-
4-(4-benzoylphenoxy)benzoic acid
-
4-(4-phenoxybenzoyl)benzoic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000053 mM, not inhibitory to isoform 1
4-(4-[[2,6-bis(trifluoromethyl)benzyl]oxy]benzoyl)benzoic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000113 mM, isoform 1, 12% inhibition at 0.01 mM
4-(biphenyl-4-yloxy)-2-chlorobenzoic acid
-
4-(biphenyl-4-yloxy)-2-fluorobenzoic acid
-
4-(biphenyl-4-yloxy)-3-methoxybenzoic acid
-
4-(methoxycarbonyl)phenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
129% inhibition at 0.010 mM
4-androsten-3-one-17-carboxylic acid
competitive
4-aza-20-hydroxyimino-5-pregnene-3-one
-
an 4-azasteroid
4-bromo-3,20-dioxopregn-4-en-17-yl 4-chlorobenzoate
-
4-bromo-3,20-dioxopregn-4-en-17-yl 4-fluorobenzoate
-
4-bromo-3,20-dioxopregna-1,4-dien-17-yl acetate
-
4-fluorophenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
93% inhibition at 0.010 mM
4-methylphenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
102% inhibition at 0.010 mM
4-trifluoromethyl-N-(tert-butyl)-4-androsten-17beta-carboxamide
-
4-[(1-benzyl-1H-indol-5-yl)oxy]-3-chlorobenzoic acid
-
4-[1-(6,6-dimethyl-6H-dibenzo[b,d]pyran-3-yl)methylindol-3-yl]-butyric acid
i.e. FR119680
4-[2-(1-methyl-6-oxopiperidin-3-yl)ethyl]-N,N-di(propan-2-yl)benzamide
-
4-[2-(5-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
-
4-[2-(6-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
-
4-[3-(1-methyl-6-oxopiperidin-3-yl)butan-2-yl]-N,N-di(propan-2-yl)benzamide
-
4-[3-(4-[(1R)-1-[4-(2-methylpropyl)phenyl]ethoxy]benzoyl)-1H-indol-1-yl]butanoic acid
-
4-[3-(benzyloxy)benzoyl]benzoic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000131 mM, not inhibitory to isoform 1
4-[3-([(2R)-2-methyl-2-[4-(2-methylpropyl)phenyl]-1,3-benzodioxol-5-yl]carbonyl)-1H-indol-1-yl]butanoic acid
-
4-[3-ethyl-4-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrol-1-yl]butanoic acid
-
4-[3-[3-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-4-(propan-2-yl)-1H-pyrrol-1-yl]butanoic acid
-
4-[3-[3-[bis (4-isobutylphenyl)methyl amino] benzoyl]-lH-indol-l-yl] butyric acid
i.e. FK-143
4-[3-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrol-1-yl]butanoic acid
-
4-[3-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-4-(propan-2-yl)-1H-pyrrol-1-yl]butanoic acid
-
4-[4-(4-methylbenzoyl)phenoxy]benzoic acid
-
4-[4-(benzyloxy)benzoyl]benzoic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000119 mM, not inhibitory to isoform 1
4-[4-(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)phenoxy]benzoic acid
-
4-[4-[di(propan-2-yl)carbamoyl]-2-ethylphenyl]cyclohex-1-ene-1-carboxylic acid
-
4-[[1-(2-propylpentanoyl)piperidin-4-ylidene]methyl]benzoic acid
-
4-[[1-(biphenyl-4-ylcarbamoyl)piperidin-4-ylidene]methyl]benzoic acid
-
4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]-3-fluorobenzoic acid
-
4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]benzoic acid
-
4-[[1-(diphenylacetyl)piperidin-4-ylidene]methyl]benzoic acid
-
5-(2-ethyl-3-[3-[(4-hexylundecyl)amino]benzoyl]-1H-pyrrol-1-yl)pentanoate
-
5-(4-chlorophenyl)-1-methylpiperidin-2-one
-
5-(4-chlorophenyl)-1-methylpiperidine-2-thione
-
5-(benzyloxy)-1H-indole-2-carboxylic acid
-
5-bromo-N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]pentanamide
-
5alpha,6alpha-epoxy-3beta-acetoxy-20-hydroxyiminopregnane
-
-
5alpha,6alpha-epoxy-3beta-acetoxypregnan-20-one
-
-
5alpha,6alpha-epoxy-3beta-hydroxypregnan-20-one
-
-
5beta,6beta-epoxy-3beta-acetoxy-20-hydroxyiminopregnane
-
-
5beta,6beta-epoxy-3beta-acetoxypregnan-20-one
-
-
6,20-dioxopregn-4-en-3-yl 4-bromobenzoate
-
6,20-dioxopregn-4-en-3-yl 4-fluorobenzoate
-
6,20-dioxopregn-4-en-3-yl 5-chloropentanoate
-
6,20-dioxopregna-4,16-dien-3-yl 3-bromopropanoate
-
-
6,20-dioxopregna-4,16-dien-3-yl 3-chloropropanoate
-
-
6,20-dioxopregna-4,16-dien-3-yl 3-iodopropanoate
-
-
6,20-dioxopregna-4,16-dien-3-yl 4-bromobenzoate
-
6,20-dioxopregna-4,16-dien-3-yl 4-fluorobenzoate
-
6,20-dioxopregna-4,16-dien-3-yl 4-methylbenzoate
-
6,20-dioxopregna-4,16-dien-3-yl acetate
6,20-dioxopregna-4,16-dien-3-yl benzoate
6,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
6-(benzyloxy)-5-methoxy-1-methyl-1H-indole-2-carboxylic acid
-
6-([5-[(1R,4aR,6aR,7R,11aR)-1,4a,6a-trimethyl-1-oxidohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]hexanoyl]amino)hexanoic acid
-
6-([5-[(1S,4aR,6aR,7R,11aR)-1,4a,6a-trimethyl-1-oxidohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]hexanoyl]amino)hexanoic acid
-
6-bromo-3,20-dioxopregna-4,6-dien-17-yl acetate
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-chlorobenzoate
-
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
6-chloro-3,20-dioxopregna-4,6-dien-17-yl benzoate
6-hydroxy-9,10-dimethoxy-3,3-dimethyl-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(13H)-one
-
6-methylidene-3,20-dioxopregn-4-en-17-yl 4-bromobenzoate
-
6-[(1R,4aR,6aR,7R,11aR)-7-[6-[(4-cyanobenzyl)oxy]hexan-2-yl]-4a,6a-dimethyl-1-oxidohexadecahydro-1H-indeno[5,4-f]quinolin-1-yl]hexanoic acid
-
6-[(1S,4aR,6aR,7R,11aR)-7-[6-[(4-cyanobenzyl)oxy]hexan-2-yl]-4a,6a-dimethyl-1-oxidohexadecahydro-1H-indeno[5,4-f]quinolin-1-yl]hexanoic acid
-
6-[3-(N,N-dicyclohexylaminocarbonyl) phenyl]-3,4-dihydro-naphthalene-2-carboxylate
-
6-[3-(N,N-dicyclohexylaminocarbonyl)phenyl]-3,4-dihydro-naphthalene-2-carboxylic acid
-
6-[4-(N,N-diisopropylamino-carbonyl) phenyl]naphthalene-2-carboxylic acid
-
6-[4-(N,N-diisopropylcarbamoyl) phenyl]-1H-quinolin-2-one
-
6-[4-(N,N-diisopropylcarbamoyl) phenyl]-N-methyl-quinolin-2-one
-
6-[4-[di(propan-2-yl)carbamoyl]phenyl]-3,4-dihydronaphthalene-2-carboxylic acid
-
7-bromo-9,10-dihydrophenanthrene-2-carboxylic acid
-
7-chloro-3,4,4a,9-tetrahydrophenanthrene-2-carboxylic acid
-
7-chloro-9,10-dihydrophenanthrene-2-carboxylic acid
-
7-[(3-methylbut-2-en-1-yl)oxy]-2H-chromen-2-one
-
7-[(E)-2-phenylethenyl]-9,10-dihydrophenanthrene-2-carboxylic acid
-
8-allyl-7-hydroxycoumarin
-
8-bromo-4-methyl-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
8-chloro-1,2,5,6,6a,7,8,9,10,10a-decahydro-3H-pyrido[1,2-a]quinolin-3-one
-
8-chloro-1,2,5,6,7,8,9,10-octahydro-3H-pyrido[1,2-a]quinolin-3-one
-
8-chloro-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
8-chloro-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
8-chloro-1-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
8-chloro-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
8-chloro-4,6-dimethyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
8-chloro-4-methyl-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
8-chloro-4-methyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
8-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
9,10-dihydrophenanthrene-2-carboxylic acid
-
androst-4-ene-3,17-dione
-
estra-4,8-diene-3,17-dione
-
estra-4,9(11)-diene-3,17-dione
-
ethyl 4-[2-[([1-[bis(4-propylphenyl)methyl]-1H-benzimidazol-5-yl]carbonyl)amino]phenoxy]butanoate
-
methyl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
-
methyl(1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
-
MK386
-
significant decrease in cell proliferation of enzyme-positive prostate cancer cell lines
MK906
-
significant decrease in cell proliferation of enzyme-positive prostate cancer cell lines
N,N-dicyclohexyl-4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzamide
-
N-(1,1,1,3,3,3-hexafluorophenylpropyl)-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
i.e. PNU 157706
N-(3,3-dimethylbutyl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-(3-methylbutan-2-yl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-(3-methylbutyl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-(4-methoxycyclohexyl)-2-methyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]propanamide
-
N-(dicyclohexyl)acetyl-piperidine-4-(benzylidene-4-carboxylic acid)
-
N-butyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-cyclohexyl-N-iodo-4-(2-methoxyquinolin-6-yl)benzamide
-
N-heptyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-iodo-4-(2-methoxyquinolin-6-yl)benzamide
-
N-octyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]butanamide
-
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-phenyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]benzamide
-
N-propyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-propyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-tert-butyl-3-oxoestra-4,9(11)-diene-17-carboxamide
-
N-[1,1,1-trifluoro-2-oxobut-3-yl]-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
-
pregna-4,16-diene-3,6,20-trione
progesterone
-
inhibits the synthesis of 5alpha-dihydrotestosterone by competing with 4-en-3-one function of the testosterone for the 5alpha-reductase enzyme
Strogen forte
-
standardized extract of the plant Sabalis serrulata, 0.245 mg/ml result in 50% enzyme inhibition
-
tricyclo[3.3.1.13,7]dec-2-yl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
-
[(17beta)-17-(propan-2-ylcarbamoyl)androsta-3,5-dien-3-yl]phosphinic acid
-
[(17beta)-17-(propan-2-ylcarbamoyl)androsta-3,5-dien-3-yl]phosphonic acid
-
[3-fluoro-4-(4-phenoxybenzoyl)phenyl]acetic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000045 mM, not inhibitory to isoform 1
[3-methyl-4-(4-phenoxybenzoyl)phenyl]acetic acid
[4-(4-phenoxybenzoyl)phenyl]acetic acid
[4-(biphenyl-4-yloxy)phenyl]acetic acid
-
[4-[4-(4-bromophenoxy)benzoyl]phenyl]acetic acid
1-cyclopropyl-3-phenyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
39.7% inhibition at 100 nM in transfected SW-13 cells
1-cyclopropyl-3-phenyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
56.3% inhibition at 100 nM in transfected SW-13 cells
6-[4-(N,N-diisopropylamino-carbonyl)phenyl]naphthalene-2-carboxylic acid
-
6-[4-(N,N-diisopropylamino-carbonyl)phenyl]naphthalene-2-carboxylic acid
uncompetitive
dutasteride
i.e. 17beta-N-(2,5-bis(trifluoromethyl)-phenyl)-3-oxo-4-aza-5alpha-androst-1-ene-17-carboxamide, a competitive inhibitor of both 5alpha-reductase type I and type II isozymes, reduces DHT levels over 90% following 1 year of oral administration
dutasteride
inhibits 5alphaR1 and 5alphaR2
dutasteride
SRD5alpha2 and SRD5alpha1 both respond similarly to dutasteride
finasteride
i.e. 17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one, decreases the prostatic dihydrotestosterone level by 70-90% and reduces the prostatic size, inhibition mechanism, detailed overview
finasteride
SRD5alpha2 is more sensitive to finasteride than SRD5alpha1
(17beta)-17-[3-(4-bromophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
-
(17beta)-17-[3-(4-bromophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
(17beta)-17-[3-(4-chlorophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
-
(17beta)-17-[3-(4-chlorophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
(17beta)-17-[3-(4-ethoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
-
(17beta)-17-[3-(4-ethoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
(17beta)-17-[3-(4-ethylphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
-
(17beta)-17-[3-(4-ethylphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
(17beta)-17-[3-(4-methoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
-
(17beta)-17-[3-(4-methoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (2-fluorophenyl)acetate
-
-
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (2-fluorophenyl)acetate
-
(5alpha,6alpha)-20-oxo-5,6-epoxypregn-16-en-3-yl acetate
-
-
(5alpha,6alpha)-20-oxo-5,6-epoxypregn-16-en-3-yl acetate
-
3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
-
-
3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
-
3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
-
-
3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
-
3,20-dioxopregna-4,6-dien-17-yl benzoate
-
-
3,20-dioxopregna-4,6-dien-17-yl benzoate
-
6,20-dioxopregna-4,16-dien-3-yl acetate
-
-
6,20-dioxopregna-4,16-dien-3-yl acetate
-
6,20-dioxopregna-4,16-dien-3-yl benzoate
-
-
6,20-dioxopregna-4,16-dien-3-yl benzoate
-
6-bromo-3,20-dioxopregna-4,6-dien-17-yl acetate
-
-
6-bromo-3,20-dioxopregna-4,6-dien-17-yl acetate
i.e. ONO-3806
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
-
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
-
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl benzoate
-
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl benzoate
-
dutasteride
-
-
dutasteride
-
inhibition of both isoform 1 and 2
dutasteride
i.e. 17beta-N-(2,5-bis(trifluoromethyl)-phenyl)-3-oxo-4-aza-5alpha-androst-1-ene-17-carboxamide, a competitive inhibitor of both 5alpha-reductase type I and type II isozymes, reduces DHT levels over 90% following 1 year of oral administration
dutasteride
inhibits 5alphaR1 and 5alphaR2
dutasteride
-
inhibits type 1 5alpha-reductase
finasteride
-
-
finasteride
-
pH 5.5, isoform 2, 50% inhibition at 0.000005 mM, isoform 1, 50% inhibition at 0.051 mM
finasteride
-
i.e. 17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one or MK-906. A competitive inhibitor of 5alpha-reductase type II with 10fold higher affinity than type I due to formation of stable complex with enzyme
finasteride
i.e. 17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one, decreases the prostatic DHT level by 70-90% and reduces the prostatic size, inhibition mechanism, detailed overview
finasteride
-
inhibits type 2 5alpha-reductase
kaempferol
-
-
kaempferol
-
inhibition of both isoforms I and II
pregna-4,16-diene-3,6,20-trione
-
-
pregna-4,16-diene-3,6,20-trione
-
[3-methyl-4-(4-phenoxybenzoyl)phenyl]acetic acid
-
[3-methyl-4-(4-phenoxybenzoyl)phenyl]acetic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000027 mM, not inhibitory to isoform 1
[4-(4-phenoxybenzoyl)phenyl]acetic acid
-
[4-(4-phenoxybenzoyl)phenyl]acetic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000023 mM, not inhibitory to isoform 1
[4-[4-(4-bromophenoxy)benzoyl]phenyl]acetic acid
-
[4-[4-(4-bromophenoxy)benzoyl]phenyl]acetic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000005 mM, not inhibitory to isoform 1
additional information
4-aza-3-oxo-1-ene compounds are the major class of synthetic SRD5alpha inhibitors, they require a structure similar to 3-oxo-4-ene with a secondary 17beta-substituent to successfully bind to the SRD5alpha-NADPH or SRD5alpha-NADP+ complexes
-
additional information
steroidal and non-steroidal 5alpha-reductase inhibitors as they inhibit the conversion of testosterone to 5alpha-dihydrotestosterone, detailed overview. 4-Aza, 6-aza and charged 3-substituents derivatives are highly selective for type II enzyme. Potent inhibitors of steroid 5alpha-reductase are found among the transition state analogues as molecules mimicking the transition state of the enzymatic processes exhibit a greater binding to the enzyme and hence produce greater inhibition. The enzyme 5alpha-reductase binds the 3-keto-DELTA4 steroids in such a way that the carbonyl group is brought into vicinity of a positively charged centre on the enzyme whereby the conjugated ketone becomes activated. Poor inhibition by (4aS,6aS,7S,11aS)-7-hydroxy-4a,6a-dimethylhexadecahydro-2H-indeno[4,5-h]isoquinolin-2-one, (4aS,6aS,7S,11aS)-4a,6a-dimethylhexadecahydro-1H-indeno[4,5-h]isoquinolin-7-ol, and (4aS,6aS,7S,11aR)-7-hydroxy-4a,6a-dimethyl-1,2,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-3H-indeno[5,4-f]isoquinolin-3-one. No inhibition (17E)-17-(hydroxyimino)androst-5-en-3-ol, (20Z)-20-(hydroxyimino)pregn-5-en-3-ol, (20Z)-20-(hydroxyimino)pregna-5,16-dien-3-ol, 20-(hydroxyimino)pregna-5,14-dien-3-ol, and 20-(hydroxyimino)pregna-5,14,16-trien-3-ol, and by 2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(prop-2-en-1-yl)acetamide, 2-[4-(1-methyl-6-oxopiperidin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 2-[4-(1,2-dimethyl-6-oxo-1,2,3,6-tetrahydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 1-methyl-5-[4-(phenylacetyl)phenyl]pyridin-2(1H)-one, 2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate, and 3-(2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethoxy)propyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate, as well as 8-chloro-1,2,5,6,7,8,9,10-octahydro-3H-pyrido[1,2-a]quinolin-3-one and 8-chloro-1,2,5,6,6a,7,8,9,10,10a-decahydro-3H-pyrido[1,2-a]quinolin-3-one
-
additional information
steroidal and non-steroidal 5alpha-reductase inhibitors as they inhibit the conversion of testosterone to 5alpha-dihydrotestosterone, detailed overview. 4-Aza, 6-aza and charged 3-substituents derivatives are highly selective for type II enzyme. Potent inhibitors of steroid 5alpha-reductase are found among the transition state analogues as molecules mimicking the transition state of the enzymatic processes exhibit a greater binding to the enzyme and hence produce greater inhibition. The enzyme 5alpha-reductase binds the 3-keto-DELTA4 steroids in such a way that the carbonyl group is brought into vicinity of a positively charged centre on the enzyme whereby the conjugated ketone becomes activated. Poor inhibition by (4aS,6aS,7S,11aS)-7-hydroxy-4a,6a-dimethylhexadecahydro-2H-indeno[4,5-h]isoquinolin-2-one, (4aS,6aS,7S,11aS)-4a,6a-dimethylhexadecahydro-1H-indeno[4,5-h]isoquinolin-7-ol, and (4aS,6aS,7S,11aR)-7-hydroxy-4a,6a-dimethyl-1,2,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-3H-indeno[5,4-f]isoquinolin-3-one. No inhibition (17E)-17-(hydroxyimino)androst-5-en-3-ol, (20Z)-20-(hydroxyimino)pregn-5-en-3-ol, (20Z)-20-(hydroxyimino)pregna-5,16-dien-3-ol, 20-(hydroxyimino)pregna-5,14-dien-3-ol, and 20-(hydroxyimino)pregna-5,14,16-trien-3-ol, and by 2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(prop-2-en-1-yl)acetamide, 2-[4-(1-methyl-6-oxopiperidin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 2-[4-(1,2-dimethyl-6-oxo-1,2,3,6-tetrahydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 1-methyl-5-[4-(phenylacetyl)phenyl]pyridin-2(1H)-one, 2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate, and 3-(2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethoxy)propyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate, as well as 8-chloro-1,2,5,6,7,8,9,10-octahydro-3H-pyrido[1,2-a]quinolin-3-one and 8-chloro-1,2,5,6,6a,7,8,9,10,10a-decahydro-3H-pyrido[1,2-a]quinolin-3-one
-
additional information
-
steroidal and non-steroidal 5alpha-reductase inhibitors as they inhibit the conversion of testosterone to 5alpha-dihydrotestosterone, detailed overview. 4-Aza, 6-aza and charged 3-substituents derivatives are highly selective for type II enzyme. Potent inhibitors of steroid 5alpha-reductase are found among the transition state analogues as molecules mimicking the transition state of the enzymatic processes exhibit a greater binding to the enzyme and hence produce greater inhibition. The enzyme 5alpha-reductase binds the 3-keto-DELTA4 steroids in such a way that the carbonyl group is brought into vicinity of a positively charged centre on the enzyme whereby the conjugated ketone becomes activated. Poor inhibition by (4aS,6aS,7S,11aS)-7-hydroxy-4a,6a-dimethylhexadecahydro-2H-indeno[4,5-h]isoquinolin-2-one, (4aS,6aS,7S,11aS)-4a,6a-dimethylhexadecahydro-1H-indeno[4,5-h]isoquinolin-7-ol, and (4aS,6aS,7S,11aR)-7-hydroxy-4a,6a-dimethyl-1,2,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-3H-indeno[5,4-f]isoquinolin-3-one. No inhibition (17E)-17-(hydroxyimino)androst-5-en-3-ol, (20Z)-20-(hydroxyimino)pregn-5-en-3-ol, (20Z)-20-(hydroxyimino)pregna-5,16-dien-3-ol, 20-(hydroxyimino)pregna-5,14-dien-3-ol, and 20-(hydroxyimino)pregna-5,14,16-trien-3-ol, and by 2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(prop-2-en-1-yl)acetamide, 2-[4-(1-methyl-6-oxopiperidin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 2-[4-(1,2-dimethyl-6-oxo-1,2,3,6-tetrahydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 1-methyl-5-[4-(phenylacetyl)phenyl]pyridin-2(1H)-one, 2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate, and 3-(2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethoxy)propyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate, as well as 8-chloro-1,2,5,6,7,8,9,10-octahydro-3H-pyrido[1,2-a]quinolin-3-one and 8-chloro-1,2,5,6,6a,7,8,9,10,10a-decahydro-3H-pyrido[1,2-a]quinolin-3-one
-
additional information
-
design and optimization of steroidal structure as 5alpha-reductase inhibitors, rationalizing the molecular properties and 5alpha-reductase inhibitory activities, three-dimensional quantitative structure-activity relationship, 3D-QSAR, study and modeling, overview
-
additional information
no inhibition of 5alphaR1 by tetracycline
-
additional information
no inhibition of 5alphaR1 by tetracycline
-
additional information
steroidal and non-steroidal 5alpha-reductase inhibitors as they inhibit the conversion of testosterone to 5alpha-dihydrotestosterone, detailed overview. Inhibitors with 4-methyl-4-aza functionality are very potent for type I enzyme. Potent inhibitors of steroid 5alpha-reductase are found among the transition state analogues as molecules mimicking the transition state of the enzymatic processes exhibit a greater binding to the enzyme and hence produce greater inhibition. The enzyme 5alpha-reductase binds the 3-keto-DELTA4 steroids in such a way that the carbonyl group is brought into vicinity of a positively charged centre on the enzyme whereby the conjugated ketone becomes activated. Poor inhibition by (4aS,6aS,7S,11aS)-7-hydroxy-4a,6a-dimethylhexadecahydro-2H-indeno[4,5-h]isoquinolin-2-one, (4aS,6aS,7S,11aS)-4a,6a-dimethylhexadecahydro-1H-indeno[4,5-h]isoquinolin-7-ol, (4aS,6aS,7S,11aR)-7-hydroxy-4a,6a-dimethyl-1,2,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-3H-indeno[5,4-f]isoquinolin-3-one, and (4aS,6aS,7S,11aR)-4a,6a-dimethyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[5,4-f]isoquinolin-7-ol. No inhibition by (17E)-17-(hydroxyimino)androst-5-en-3-ol, (20Z)-20-(hydroxyimino)pregn-5-en-3-ol, (20Z)-20-(hydroxyimino)pregna-5,16-dien-3-ol, 20-(hydroxyimino)pregna-5,14-dien-3-ol, and 20-(hydroxyimino)pregna-5,14,16-trien-3-ol
-
additional information
steroidal and non-steroidal 5alpha-reductase inhibitors as they inhibit the conversion of testosterone to 5alpha-dihydrotestosterone, detailed overview. Inhibitors with 4-methyl-4-aza functionality are very potent for type I enzyme. Potent inhibitors of steroid 5alpha-reductase are found among the transition state analogues as molecules mimicking the transition state of the enzymatic processes exhibit a greater binding to the enzyme and hence produce greater inhibition. The enzyme 5alpha-reductase binds the 3-keto-DELTA4 steroids in such a way that the carbonyl group is brought into vicinity of a positively charged centre on the enzyme whereby the conjugated ketone becomes activated. Poor inhibition by (4aS,6aS,7S,11aS)-7-hydroxy-4a,6a-dimethylhexadecahydro-2H-indeno[4,5-h]isoquinolin-2-one, (4aS,6aS,7S,11aS)-4a,6a-dimethylhexadecahydro-1H-indeno[4,5-h]isoquinolin-7-ol, (4aS,6aS,7S,11aR)-7-hydroxy-4a,6a-dimethyl-1,2,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-3H-indeno[5,4-f]isoquinolin-3-one, and (4aS,6aS,7S,11aR)-4a,6a-dimethyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[5,4-f]isoquinolin-7-ol. No inhibition by (17E)-17-(hydroxyimino)androst-5-en-3-ol, (20Z)-20-(hydroxyimino)pregn-5-en-3-ol, (20Z)-20-(hydroxyimino)pregna-5,16-dien-3-ol, 20-(hydroxyimino)pregna-5,14-dien-3-ol, and 20-(hydroxyimino)pregna-5,14,16-trien-3-ol
-
additional information
-
steroidal and non-steroidal 5alpha-reductase inhibitors as they inhibit the conversion of testosterone to 5alpha-dihydrotestosterone, detailed overview. Inhibitors with 4-methyl-4-aza functionality are very potent for type I enzyme. Potent inhibitors of steroid 5alpha-reductase are found among the transition state analogues as molecules mimicking the transition state of the enzymatic processes exhibit a greater binding to the enzyme and hence produce greater inhibition. The enzyme 5alpha-reductase binds the 3-keto-DELTA4 steroids in such a way that the carbonyl group is brought into vicinity of a positively charged centre on the enzyme whereby the conjugated ketone becomes activated. Poor inhibition by (4aS,6aS,7S,11aS)-7-hydroxy-4a,6a-dimethylhexadecahydro-2H-indeno[4,5-h]isoquinolin-2-one, (4aS,6aS,7S,11aS)-4a,6a-dimethylhexadecahydro-1H-indeno[4,5-h]isoquinolin-7-ol, (4aS,6aS,7S,11aR)-7-hydroxy-4a,6a-dimethyl-1,2,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-3H-indeno[5,4-f]isoquinolin-3-one, and (4aS,6aS,7S,11aR)-4a,6a-dimethyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[5,4-f]isoquinolin-7-ol. No inhibition by (17E)-17-(hydroxyimino)androst-5-en-3-ol, (20Z)-20-(hydroxyimino)pregn-5-en-3-ol, (20Z)-20-(hydroxyimino)pregna-5,16-dien-3-ol, 20-(hydroxyimino)pregna-5,14-dien-3-ol, and 20-(hydroxyimino)pregna-5,14,16-trien-3-ol
-
additional information
-
synthesis, enzyme inhibitory, and cell cytotoxicity of pregnan compounds, IC50 values for growth inhibition, overview
-
additional information
-
green tea seed extract hydrolysate shows a good inhibition effect on HEK 293 cell lines on both type 1 and type 2 5alpha-reductase
-
additional information
-
hot water extract and 20% (v/v) ethanol extract of Curcuma longa significantly inhibit 5-alpha reductase activity
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Masculinizing genitoplasty in intersex patients.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
5?-Reductase-2 deficiency: is gender assignment recommended in infancy? Two case-reports and review of the literature.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
5alpha-reductase activity in the prostate.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
5alpha-reductase activity of genital and nongenital skin fibroblasts from patients with 5alpha-reductase deficiency, androgen insensitivity, or unknown forms of male pseudohermaphroditism.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
5alpha-reductase type 2 mutations are present in some boys with isolated hypospadias.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
A new mutation of 5-alpha-reductase type 2 (A62E) in a large Egyptian kindred.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
A novel frameshift mutation in the 5alpha-reductase type 2 gene in Korean sisters with male pseudohermaphroditism.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
A novel homozygous disruptive mutation in the SRD5A2-gene in a partially virilized patient with 5alpha-reductase deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
A novel mutation of 5alpha-steroid reductase 2 deficiency (CD 65 ALA-PRO) with severe virilization defect in a Turkish family and difficulty in gender assignment.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
A study of gender outcome of Egyptian patients with 46,XY disorder of sex development.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Androgens and the evolution of male-gender identity among male pseudohermaphrodites with 5alpha-reductase deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Binding of androgens in 5 alpha-reductase-deficient human genital skin fibroblasts: inhibition by progesterone and its metabolites.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Choice of gender in 5alpha-reductase deficiency: a moving target.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Clinical characterization and analysis of the SRD5A2 gene in six Korean patients with 5alpha-reductase type 2 deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Clinical, biochemical and morphologic diagnostic markers in an infant male pseudohermaphrodite patient with compound heterozygous mutations (G115D/R246W) in SRD5A2 gene.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Definitive diagnosis of enzymatic deficiencies of steroidogenesis in at-risk newborns and infants by urinary marker analysis using GC/MS-SIM.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Diagnosis of 5alpha-reductase deficiency in a teenage Turkish girl.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Diagnosis of 5alpha-reductase type 2 deficiency: contribution of anti-Müllerian hormone evaluation.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Difficulties in Diagnosis and Treatment of 5alpha-Reductase Type 2 Deficiency in a Newborn with 46,XY DSD.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Disorders linked to insufficient androgen action in male children.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Early diagnosis of 5alpha-reductase deficiency in newborns.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Endocrinology of male infertility: evaluation and treatment.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Etiological studies of severe or familial hypospadias.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Evaluation of the tubular and interstitial functions of the testis in 46,XY patients with ambiguous genitalia.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Evidence that steroid 5alpha-reductase isozyme genes are differentially methylated in human lymphocytes.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Five novel mutations of SRD5A2 found in eight Chinese patients with 46,XY disorders of sex development.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Gender identity of children and young adults with 5alpha-reductase deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Genetic analysis of the SRD5A2 gene in Indian patients with 5alpha-reductase deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Genotype-phenotype correlation, gonadal malignancy risk, gender preference, and testosterone/dihydrotestosterone ratio in steroid 5-alpha-reductase type 2 deficiency: a multicenter study from Turkey.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Homozygous Ala65Pro Mutation with V89L Polymorphism in SRD5A2 Deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Homozygous mutation (A228T) in the 5alpha-reductase type 2 gene in a boy with 5alpha-reductase deficiency: genotype-phenotype correlations.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Hypospadias.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Identification of mutations in the SRD5A2 gene in Thai patients with male pseudohermaphroditism.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Induction of a deficiency of steroid delta 4-5 alpha-reductase activity in liver by a porphyrinogenic drug.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Intranuclear binding of [3H]dihydrotestosterone by cultured human fibroblasts.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Long-term surgical results and patient satisfaction with male pseudohermaphroditism or true hermaphroditism: a cohort of 63 patients.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Masculinizing genitoplasty in intersex patients.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Minimal External Masculinization in a SRY-negative XX Male Podenco Dog.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Molecular analysis of 5alpha-reductase type 2 gene in eight unrelated egyptian children with suspected 5alpha-reductase deficiency: prevalence of the G34R mutation.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Molecular analysis of the AR and SRD5A2 genes in patients with 46,XY disorders of sex development.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Molecular characterization of 6 unrelated Italian patients with 5alpha-reductase type 2 deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
New frameshift mutation in the 5alpha-reductase type 2 gene in a Brazilian patient with 5alpha-reductase deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
New mutations, hotspots, and founder effects in Brazilian patients with steroid 5alpha-reductase deficiency type 2.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Phenotypic variability in 17beta-hydroxysteroid dehydrogenase-3 deficiency and diagnostic pitfalls.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Phenotypic variation in a family with partial androgen insensitivity syndrome explained by differences in 5alpha dihydrotestosterone availability.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Pituitary-gonadal axis in male undermasculinisation.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Practical approach to steroid 5alpha-reductase type 2 deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Prolonged human chorionic gonadotrophin stimulation as a tool for investigating and managing undescended testes.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
RECOGNITION OF 5-ALPHA REDUCTASE-2 DEFICIENCY IN AN ADULT FEMALE 46XY DSD CLINIC.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Screening for mutations for 17 ?-hydroxysteroid dehydrogenase and androgen receptor in an adult female 46, XY DSD clinic.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Sigmoid colon vaginoplasty in children.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Squamous cell carcinoma of the vagina in a male pseudohermaphrodite with 5alpha-reductase deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Stable maintenance of 5alpha-reductase activity in long-term subcultures of fibroblasts derived from the foreskin.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Steroid 5alpha-reductase deficiency in man. An inherited form of male pseudohermaphroditism.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Steroidogenesis of the testis -- new genes and pathways.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
The hair follicle: a paradoxical androgen target organ.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
The role of the pediatrician in the management of children with genital ambiguities.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Undervirilization in XY newborns may hide a 5alpha-reductase deficiency: report of three new SRD5A2 gene mutations.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Uniparental disomy in steroid 5alpha-reductase 2 deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
[5alpha-reductase type 2 deficiency: experiences from Campinas (SP) and Salvador (BA)]
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
[Steroid 5alpha-reductase deficiency]
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Characterising SRD5A2 Gene Variants in 37 Indonesian Patients with 5-Alpha-Reductase Type 2 Deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Molecular characterization of 6 unrelated Italian patients with 5alpha-reductase type 2 deficiency.
3beta-hydroxysteroid 3-dehydrogenase deficiency
Evaluation of the tubular and interstitial functions of the testis in 46,XY patients with ambiguous genitalia.
3beta-hydroxysteroid 3-dehydrogenase deficiency
Masculinizing genitoplasty in intersex patients.
Abortion, Spontaneous
Fetal alpha 5-reductase Val89Leu mutation is associated with late miscarriage.
Acne Vulgaris
19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
Acne Vulgaris
5alpha-reductase: history and clinical importance.
Acne Vulgaris
Acne: effect of hormones on pathogenesis and management.
Acne Vulgaris
Androgen metabolism in sebaceous glands from subjects with and without acne.
Acne Vulgaris
Immunolocalization of 5alpha-reductase isozymes in acne lesions and normal skin.
Acne Vulgaris
Inhibition of 5alpha-reductase activity in SZ95 sebocytes and HaCaT keratinocytes in vitro.
Acne Vulgaris
Longer TA repeat but not V89L polymorphisms in the SRD5A2 gene may confer acne risk in the Chinese population.
Acne Vulgaris
MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
Acne Vulgaris
MK386: a potent, selective inhibitor of the human type 1 5alpha-reductase.
Acne Vulgaris
The association of serum androsterone glucuronide with inflammatory lesions in women with adult acne.
Adenocarcinoma
Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor.
Adrenal Hyperplasia, Congenital
Definitive diagnosis of enzymatic deficiencies of steroidogenesis in at-risk newborns and infants by urinary marker analysis using GC/MS-SIM.
Adrenal Hyperplasia, Congenital
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Adrenoleukodystrophy
New findings on X-linked Adrenoleukodystrophy: 5alpha-reductase isoform 2 relative gene expression is modified in affected fibroblasts.
Alopecia
19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
Alopecia
5alpha-Reductase Isozymes in the Prostate.
Alopecia
5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.
Alopecia
5alpha-reductase: history and clinical importance.
Alopecia
A new look at the 5alpha-reductase inhibitor finasteride.
Alopecia
Acne: effect of hormones on pathogenesis and management.
Alopecia
Analysis of genetic polymorphisms of steroid 5alpha-reductase type 1 and 2 genes in Korean men with androgenetic alopecia.
Alopecia
Biochemical roles of testosterone and epitestosterone to 5 alpha-reductase as indicators of male-pattern baldness.
Alopecia
Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study.
Alopecia
Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily.
Alopecia
Changes of metabolic profile in men treated for androgenetic alopecia with 1 mg finasteride.
Alopecia
Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men.
Alopecia
Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss.
Alopecia
Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia.
Alopecia
Current management of androgenetic alopecia in men.
Alopecia
Delayed telogen replacement in a boy's scalp.
Alopecia
Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia.
Alopecia
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Alopecia
Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite.
Alopecia
Effect of Cuscuta reflexa Roxb on androgen-induced alopecia.
Alopecia
Effect of testosterone metabolites on ABC half-transporter relative gene expression in X-linked adrenoleukodystrophy.
Alopecia
Establishment of type II 5alpha-reductase over-expressing cell line as an inhibitor screening model.
Alopecia
Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration.
Alopecia
Expression of androgen receptor coactivator ARA70/ELE1 in androgenic alopecia.
Alopecia
Finasteride in the treatment of alopecia.
Alopecia
Finasteride in the treatment of men with frontal male pattern hair loss.
Alopecia
Finasteride treatment and neuroactive steroid formation.
Alopecia
Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women.
Alopecia
Finasteride, a Type 2 5alpha-reductase inhibitor, in the treatment of men with androgenetic alopecia.
Alopecia
Finasteride: a review of its use in male pattern hair loss.
Alopecia
Genetic analysis of male pattern baldness and the 5alpha-reductase genes.
Alopecia
Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG).
Alopecia
Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.
Alopecia
Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?
Alopecia
Relationship of Early-Onset Baldness to Prostate Cancer in African-American Men.
Alopecia
Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics.
Alopecia
Selected variants of the steroid-5-alpha-reductase isoforms SRD5A1 and SRD5A2 and the sex steroid hormone receptors ESR1, ESR2 and PGR: no association with female pattern hair loss identified.
Alopecia
Spermatozoa and chronic treatment with finasteride: a TEM and FISH study.
Alopecia
Testosterone metabolism in human skin cells in vitro and its interaction with estradiol and dutasteride.
Alopecia
The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
Alopecia
The extract of Thujae occidentalis semen inhibited 5alpha-reductase and androchronogenetic alopecia of B6CBAF1/j hybrid mouse.
Alopecia
The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
Alopecia
The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles.
Alopecia
Treatment of male rats with finasteride, an inhibitor of 5alpha-reductase enzyme, induces long-lasting effects on depressive-like behavior, hippocampal neurogenesis, neuroinflammation and gut microbiota composition.
Alopecia
Ultrasound-activated particles as CRISPR/Cas9 delivery system for androgenic alopecia therapy.
Alopecia
Urinary steroid measurements in some endocrine and psychiatric diseases.
Alopecia
Urinary steroids in women with androgenic alopecia.
Alopecia
Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss).
Alopecia
Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old.
Androgen-Insensitivity Syndrome
Clinical and Laboratorial Features That May Differentiate 46,XY DSD due to Partial Androgen Insensitivity and 5?-Reductase Type 2 Deficiency.
Androgen-Insensitivity Syndrome
Clinical, biochemical and morphologic diagnostic markers in an infant male pseudohermaphrodite patient with compound heterozygous mutations (G115D/R246W) in SRD5A2 gene.
Androgen-Insensitivity Syndrome
Disorders linked to insufficient androgen action in male children.
Androgen-Insensitivity Syndrome
Etiological studies of severe or familial hypospadias.
Androgen-Insensitivity Syndrome
Evaluation of the tubular and interstitial functions of the testis in 46,XY patients with ambiguous genitalia.
Androgen-Insensitivity Syndrome
Investigation of androgen receptor gene mutations in a series of 21 patients with 46,XY disorders of sex development.
Androgen-Insensitivity Syndrome
Masculinizing genitoplasty in intersex patients.
Androgen-Insensitivity Syndrome
Molecular analysis of the AR and SRD5A2 genes in patients with 46,XY disorders of sex development.
Androgen-Insensitivity Syndrome
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Androgen-Insensitivity Syndrome
Screening for mutations in candidate genes for hypospadias.
Androgen-Insensitivity Syndrome
Stable maintenance of 5alpha-reductase activity in long-term subcultures of fibroblasts derived from the foreskin.
Androgen-Insensitivity Syndrome
Steroid metabolism in the gonads of a patient with testicular feminization. II. Metabolism of c19- and c18-steroids in vitro.
Androgen-Insensitivity Syndrome
The role of the pediatrician in the management of children with genital ambiguities.
Androgen-Insensitivity Syndrome
Transcription of androgen receptor and 5alpha-reductase II in genital fibroblasts from patients with androgen insensitivity syndrome.
aromatase deficiency
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Azoospermia
5Alpha-reductase type 2 genes in Japanese males do not appear to be associated with cryptorchidism.
Azoospermia
Mutation screening for the 5alpha-reductase type 2 gene in Japanese men with idiopathic azoospermia.
Azoospermia
Steroid 5alpha-reductase 2 gene melting polymorphisms in male subjects with azoospermia or oligospermia.
Breast Neoplasms
5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production.
Breast Neoplasms
5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.
Breast Neoplasms
A49T, V89L and TA repeat polymorphisms of steroid 5alpha-reductase type II and breast cancer risk in Japanese women.
Breast Neoplasms
Activity and expression of progesterone metabolizing 5alpha-reductase, 20alpha-hydroxysteroid oxidoreductase and 3alpha(beta)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells.
Breast Neoplasms
Androgens in human breast carcinoma.
Breast Neoplasms
Associations between the SRD5A2 gene V89L and TA repeat polymorphisms and breast cancer risk: a meta-analysis.
Breast Neoplasms
Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment.
Breast Neoplasms
Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma.
Breast Neoplasms
Genetic Variation in the Progesterone Receptor and Metabolism Pathways and Hormone Therapy in Relation to Breast Cancer Risk.
Breast Neoplasms
Intracrinology of estrogens and androgens in breast carcinoma.
Breast Neoplasms
Multilocus genotypes spanning estrogen metabolism associated with breast cancer and fibroadenoma.
Breast Neoplasms
Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy.
Breast Neoplasms
SRD5A2 gene polymorphisms affect the risk of breast cancer.
Breast Neoplasms
TA repeat polymorphism of the 5alpha-reductase gene and breast cancer.
Breast Neoplasms
The role of progesterone metabolites in breast cancer: potential for new diagnostics and therapeutics.
Breast Neoplasms
The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.
Breast Neoplasms
The V89L polymorphism in the 5-alpha-reductase type 2 gene and risk of breast cancer.
Carcinogenesis
Inhibition of rat prostate carcinogenesis by a 5alpha-reductase inhibitor, FK143.
Carcinogenesis
Involvement of Egr-1 in HGF-induced elevation of the human 5alpha-R1 gene in human hepatocellular carcinoma cells.
Carcinogenesis
Mammary steroid metabolizing enzymes in relation to hyperplasia and tumorigenesis in the dog.
Carcinogenesis
Polymorphisms in androgen metabolism genes AR, CYP1B1, CYP19, and SRD5A2and prostate cancer risk and aggressiveness in Bulgarian patients.
Carcinogenesis
Promoting effects of antiandrogenic agents on rat ventral prostate carcinogenesis induced by 3,2'-dimethyl-4-aminobiphenyl (DMAB).
Carcinoma
A preliminary investigation of the enzymatic inhibition of 5alpha-reduction and growth of prostatic carcinoma cell line LNCap-FGC by natural astaxanthin and Saw Palmetto lipid extract in vitro.
Carcinoma
Alterations of peripheral testosterone matabolism after induced hypoprolactinemia in patients with prostatic carcinoma.
Carcinoma
Anti-androgenic activity of fatty acids.
Carcinoma
Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Carcinoma
Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate.
Carcinoma
Combined treatment of Dunning R3327 rat prostatic tumor with the 5alpha-reductase inhibitor PNU 157706 and the antiandrogen bicalutamide.
Carcinoma
Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats.
Carcinoma
Effect of the dual 5alpha-reductase inhibitor PNU 157706 on the growth of dunning R3327 prostatic carcinoma in the rat.
Carcinoma
Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
Carcinoma
Effects of various pesticides on human 5alpha-reductase activity in prostate and LNCaP cells.
Carcinoma
Expression of 5alpha-reductases in human epithelial ovarian cancer: its correlation with androgen receptor status.
Carcinoma
Expression of androgen receptor and 5alpha-reductases in the human normal endometrium and its disorders.
Carcinoma
In situ androgen producing enzymes in human prostate cancer.
Carcinoma
Promoting effects of antiandrogenic agents on rat ventral prostate carcinogenesis induced by 3,2'-dimethyl-4-aminobiphenyl (DMAB).
Carcinoma
Squamous cell carcinoma of the vagina in a male pseudohermaphrodite with 5alpha-reductase deficiency.
Carcinoma
Validation of the Pitts unified theory of prostate cancer, late-onset hypogonadism and carcinoma: the role of steroid 5alpha-reductase and steroid aromatase.
Carcinoma
[The effect of hormonal agents on the development of chronic laryngitis and tumor disease. Report of two cases]
Carcinoma, Ductal
5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.
Carcinoma, Hepatocellular
Feminization of hepatic S metabolism in male rats with a transplanted (MtT/F4).
Carcinoma, Hepatocellular
Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search.
Carcinoma, Hepatocellular
Involvement of Egr-1 in HGF-induced elevation of the human 5alpha-R1 gene in human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
The assessment of methylated BASP1 and SRD5A2 levels in the detection of early hepatocellular carcinoma.
Carcinoma, Intraductal, Noninfiltrating
Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
Carcinoma, Ovarian Epithelial
Expression of 5alpha-reductases in human epithelial ovarian cancer: its correlation with androgen receptor status.
Carcinoma, Squamous Cell
Squamous cell carcinoma of the vagina in a male pseudohermaphrodite with 5alpha-reductase deficiency.
Carcinoma, Squamous Cell
[The effect of hormonal agents on the development of chronic laryngitis and tumor disease. Report of two cases]
Cryptorchidism
5Alpha-reductase type 2 genes in Japanese males do not appear to be associated with cryptorchidism.
Cryptorchidism
Differences in testicular development between 5alpha-reductase 2 deficiency and isolated bilateral cryptorchidism.
Cryptorchidism
Polymorphisms of MAMLD1, SRD5A2, and AR Candidate Genes in Seven Dogs (78,XY; SRY-Positive) Affected by Hypospadias or Cryptorchidism.
Cryptorchidism
Prolonged human chorionic gonadotrophin stimulation as a tool for investigating and managing undescended testes.
Cysts
Allopregnanolone, pregnenolone sulfate, and epitestosterone in breast cyst fluid.
Denys-Drash Syndrome
Pituitary-gonadal axis in male undermasculinisation.
Diabetes Mellitus, Type 2
Androgenic correlates of genetic variation in the gene encoding 5alpha-reductase type 1.
Disorder of Sex Development, 46,XY
5alpha-reductase activity of genital and nongenital skin fibroblasts from patients with 5alpha-reductase deficiency, androgen insensitivity, or unknown forms of male pseudohermaphroditism.
Disorder of Sex Development, 46,XY
A novel frameshift mutation in the 5alpha-reductase type 2 gene in Korean sisters with male pseudohermaphroditism.
Disorder of Sex Development, 46,XY
A novel missense mutation of 5-alpha reductase type 2 gene (SRD5A2) leads to severe male pseudohermaphroditism in a Turkish family.
Disorder of Sex Development, 46,XY
Diminished 5alpha-reductase activity in extracts of fibroblasts cultured from patients with familial incomplete male pseudohermaphroditism, type 2.
Disorder of Sex Development, 46,XY
Gender identity of children and young adults with 5alpha-reductase deficiency.
Disorder of Sex Development, 46,XY
Genetic linkage mapping of the human steroid 5 alpha-reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23-->p22.
Disorder of Sex Development, 46,XY
Identification of mutations in the SRD5A2 gene in Thai patients with male pseudohermaphroditism.
Disorder of Sex Development, 46,XY
Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
Disorder of Sex Development, 46,XY
Male pseudohermaphroditism due to steroid 5alpha-reductase 2 deficiency. Diagnosis, psychological evaluation, and management.
Disorder of Sex Development, 46,XY
Masculinizing genitoplasty in intersex patients.
Disorder of Sex Development, 46,XY
New frameshift mutation in the 5alpha-reductase type 2 gene in a Brazilian patient with 5alpha-reductase deficiency.
Disorder of Sex Development, 46,XY
Normal bone density in male pseudohermaphroditism due to 5alpha- reductase 2 deficiency.
Disorder of Sex Development, 46,XY
Role of dihydrotestosterone in androgen action.
Disorder of Sex Development, 46,XY
Steroid 5alpha-reductase deficiency in man. An inherited form of male pseudohermaphroditism.
Disorder of Sex Development, 46,XY
Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism.
Disorder of Sex Development, 46,XY
Steroid 5alpha-reductase in cultured human fibroblasts. Biochemical and genetic evidence for two distinct enzyme activities.
Disorder of Sex Development, 46,XY
Uniparental disomy in steroid 5alpha-reductase 2 deficiency.
Disorders of Sex Development
A novel mutation of the 5alpha-reductase type 2 gene in two unrelated Egyptian children with ambiguous genitalia.
Disorders of Sex Development
A novel SRD5A2 mutation in a Taiwanese newborn with ambiguous genitalia.
Disorders of Sex Development
A novel SRD5A2 mutation in an Iranian family with sex development disorder.
Disorders of Sex Development
Clinical and Laboratorial Features That May Differentiate 46,XY DSD due to Partial Androgen Insensitivity and 5?-Reductase Type 2 Deficiency.
Disorders of Sex Development
Correlation of androgen receptor and SRD5A2 gene mutations with pediatric hypospadias in 46, XY DSD children.
Disorders of Sex Development
Exome sequencing identified compound heterozygous mutations in the SRD5A2 gene in a case of 46,XY ambiguous genitalia.
Disorders of Sex Development
Five novel mutations of SRD5A2 found in eight Chinese patients with 46,XY disorders of sex development.
Disorders of Sex Development
Genome analyses and androgen quantification for an infant with 5?-reductase type 2 deficiency.
Disorders of Sex Development
Long-term surgical outcome of masculinizing genitoplasty in large cohort of patients with disorders of sex development.
Disorders of Sex Development
Molecular analysis of the AR and SRD5A2 genes in patients with 46,XY disorders of sex development.
Disorders of Sex Development
Molecular diagnosis of 5alpha-reductase-2 gene mutation in two Indian families with male pseudohermaphroditism.
Disorders of Sex Development
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Disorders of Sex Development
Mutational Analysis of Androgen Receptor (AR) Gene in 46,XY Patients with Ambiguous Genitalia and Normal Testosterone Secretion: Endocrinological Characteristics of Three Patients with AR Gene Mutations.
Disorders of Sex Development
Novel compound heterozygous mutations in the SRD5A2 gene from 46,XY infants with ambiguous external genitalia.
Disorders of Sex Development
Novel mutations of the SRD5A2 and AR genes in Thai patients with 46, XY disorders of sex development.
Disorders of Sex Development
Phenotype, Sex of Rearing, Gender Re-Assignment, and Response to Medical Treatment in Extended Family Members with a Novel Mutation in the SRD5A2 Gene.
Disorders of Sex Development
Practical approach to steroid 5alpha-reductase type 2 deficiency.
Disorders of Sex Development
RECOGNITION OF 5-ALPHA REDUCTASE-2 DEFICIENCY IN AN ADULT FEMALE 46XY DSD CLINIC.
Disorders of Sex Development
Sexual differentiation.
Disorders of Sex Development
Spectrum of Pathogenic Variants in SRD5A2 in Indian Children with 46,XY Disorders of Sex Development and Clinically Suspected Steroid 5?-Reductase 2 Deficiency.
Disorders of Sex Development
Steroid 5alpha-reductase deficiency in man. An inherited form of male pseudohermaphroditism.
Disorders of Sex Development
The role of the pediatrician in the management of children with genital ambiguities.
Dwarfism
Brassinosteroid deficiency due to truncated steroid 5alpha-reductase causes dwarfism in the lk mutant of pea.
Dyskinesias
5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction.
Endocrine System Diseases
19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
Endometrial Hyperplasia
Expression of androgen receptor and 5alpha-reductases in the human normal endometrium and its disorders.
Endometrial Neoplasms
Altered expression of lysophosphatidic acid receptors, in association with the synthesis of estrogens and androgens in type 1 endometrial cancer biology.
Endometrial Neoplasms
Expression of androgen receptor and 5alpha-reductases in the human normal endometrium and its disorders.
Endometrial Neoplasms
Important roles of the AKR1C2 and SRD5A1 enzymes in progesterone metabolism in endometrial cancer model cell lines.
Endometriosis
Androgen receptor and 5alpha-reductase are expressed in pelvic endometriosis.
Endometriosis
Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line.
Epilepsy
Characterization of the 5alpha-reductase-3alpha-hydroxysteroid dehydrogenase complex in the human brain.
Epilepsy
Expression of 5alpha-reductase and 3alpha-hydroxisteroid oxidoreductase in the hippocampus of patients with chronic temporal lobe epilepsy.
Epilepsy, Absence
Finasteride inhibits the progesterone-induced spike-wave discharges in a genetic model of absence epilepsy.
Epilepsy, Temporal Lobe
Expression of 5alpha-reductase and 3alpha-hydroxisteroid oxidoreductase in the hippocampus of patients with chronic temporal lobe epilepsy.
Erectile Dysfunction
Comorbid LUTS and erectile dysfunction: optimizing their management.
Erectile Dysfunction
Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
Erectile Dysfunction
Impact of medical treatments for benign prostatic hyperplasia on sexual function.
Erectile Dysfunction
Medical management of benign prostatic hypertrophy.
Erectile Dysfunction
Noninvasive management of lower urinary tract symptoms and sexual dysfunction associated with benign prostatic hyperplasia in the primary care setting.
Erectile Dysfunction
The role of combination medical therapy in benign prostatic hyperplasia.
Fetal Death
Fetal death in mice lacking 5alpha-reductase type 1 caused by estrogen excess.
Fibroadenoma
Multilocus genotypes spanning estrogen metabolism associated with breast cancer and fibroadenoma.
Genetic Diseases, Inborn
Aetiology of hypospadias: a systematic review of genes and environment.
Gingival Overgrowth
Phenytoin-mediated androgen metabolism in gingival fibroblasts. Effects of the antiandrogen finasteride and the alkaline phosphatase inhibitor levamisole.
Gingival Overgrowth
The effects of human mast-cell products and of phenytoin on androgen 5alpha-reductase expression in human gingival fibroblasts.
Glioma
Adrenergic activation of steroid 5alpha-reductase gene expression in rat C6 glioma cells: involvement of cyclic amp/protein kinase A-mediated signaling pathway.
Glioma
Dihydrotestosterone Induces Proliferation, Migration, and Invasion of Human Glioblastoma Cell Lines.
Glioma
Influence of 17beta-estradiol on the synthesis of reduced neurosteroids in the brain (in vivo) and in glioma cells (in vitro): possible relevance to mental disorders in women.
Glioma
Influence of serum-free culture conditions on steroid 5alpha-reductase mRNA expression in rat C6 glioma cells.
Glioma
Influence of serum-free culture conditions on subcellular localization of steroid 5alpha-reductase in rat C6 glioma cells.
Glioma
Nerve growth factor induces elevation of steroid 5alpha-reductase mRNA levels in rat C6 glioma cells through expression of transcription factor Egr-1.
Glioma
Serotonergic 5-HT2A receptor stimulation induces steroid 5alpha-reductase gene expression in rat C6 glioma cells via transcription factor Egr-1.
Glioma
Trichostatin A Stimulates Steroid 5alpha-Reductase Gene Expression in Rat C6 Glioma Cells via a Mechanism Involving Sp1 and Sp3 Transcription Factors.
Glucose Intolerance
Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity.
Gonadal Dysgenesis
A study of gender outcome of Egyptian patients with 46,XY disorder of sex development.
Gonadal Dysgenesis
Evaluation of the tubular and interstitial functions of the testis in 46,XY patients with ambiguous genitalia.
Gonadal Dysgenesis
Gene dosage imbalances in patients with 46,XY gonadal DSD detected by an in-house-designed synthetic probe set for multiplex ligation-dependent probe amplification analysis.
Gonadal Dysgenesis
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Gonadal Dysgenesis
The role of the pediatrician in the management of children with genital ambiguities.
Gonadal Dysgenesis, Mixed
Masculinizing genitoplasty in intersex patients.
Gynecomastia
The identification of 5 alpha-reductase-2 and 17 beta-hydroxysteroid dehydrogenase-3 gene defects in male pseudohermaphrodites from a Turkish kindred.
Hematuria
Post-coital gross hematuria: an unusual presentation of benign prostatic hyperplasia.
Hepatitis
Sex hormone influence on hepatitis in young male A/JCr mice infected with Helicobacter hepaticus.
Hepatitis C
Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients.
Hepatitis C, Chronic
Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients.
Hirsutism
19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
Hirsutism
The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism.
Hirsutism
The evaluation and management of hirsutism.
Hirsutism
Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women.
Hypercholesterolemia
Regulation of steroid 5-alpha reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin.
Hyperprolactinemia
Alterations of peripheral testosterone matabolism after induced hypoprolactinemia in patients with prostatic carcinoma.
Hyperprolactinemia
Effects of metoclopramide on mRNA levels of 5alpha-reductase isozymes in rat brain.
Hyperprolactinemia
Effects of sulpiride on mRNA levels of steroid 5alpha-reductase isozymes in prostate of adult rats.
Hyperprolactinemia
Effects of sulpiride on prolactin and mRNA levels of steroid 5alpha-reductase isozymes in adult rat brain.
Hyperthyroidism
Comprehensive study of urinary cortisol metabolites in hyperthyroid and hypothyroid patients.
Hypertrichosis
Clinical assessment and serum hormonal profile in prepubertal hypertrichosis.
Hypogonadism
Effect of testosterone metabolites on ABC half-transporter relative gene expression in X-linked adrenoleukodystrophy.
Hypogonadism
Endocrinology of male infertility: evaluation and treatment.
Hypogonadism
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Hypogonadism
Validation of the Pitts unified theory of prostate cancer, late-onset hypogonadism and carcinoma: the role of steroid 5alpha-reductase and steroid aromatase.
Hypospadias
5alpha-reductase type 2 mutations are present in some boys with isolated hypospadias.
Hypospadias
A Novel SRD5A2 Mutation with Loss of Function Identified in Chinese Patients with Hypospadias.
Hypospadias
A49T, R227Q and TA repeat polymorphism of steroid 5 alpha-reductase type II gene and Hypospadias risk in North Indian children.
Hypospadias
Aetiology of hypospadias: a systematic review of genes and environment.
Hypospadias
Association between SRD5A2 polymorphism and hypospadias: a meta-analysis.
Hypospadias
Association of SRD5A2 gene mutations with risk of hypospadias in the Iranian population.
Hypospadias
Characterization With Gene Mutations in Han Chinese Patients With Hypospadias and Function Analysis of a Novel AR Genevariant.
Hypospadias
Correlation of androgen receptor and SRD5A2 gene mutations with pediatric hypospadias in 46, XY DSD children.
Hypospadias
Cri-du-chat (5p-) syndrome presenting with cerebellar hypoplasia and hypospadias: Prenatal diagnosis and aCGH characterization using uncultured amniocytes.
Hypospadias
Expression of Xenobiotic Biomarkers CYP1 Family in Preputial Tissue of Patients with Hypospadias and Phimosis and Its Association with DNA Methylation Level of SRD5A2 Minimal Promoter.
Hypospadias
Family History is Underestimated in Children with Isolated Hypospadias: A French Multicenter Report of 88 Families.
Hypospadias
Genetic Polymorphisms of 17beta-Hydroxysteroid Dehydrogenase 3 and the Risk of Hypospadias.
Hypospadias
Genetics of hypospadias: are single-nucleotide polymorphisms in SRD5A2, ESR1, ESR2, and ATF3 really associated with the malformation?
Hypospadias
Genotype-phenotype correlation and identification of two novel SRD5A2 mutations in 33 Chinese patients with hypospadias.
Hypospadias
Hypospadias in a Male (78,XY; SRY-Positive) Dog and Sex Reversal Female (78,XX; SRY-Negative) Dogs: Clinical, Histological and Genetic Studies.
Hypospadias
Hypospadias risk and polymorphism in SRD5A2 and CYP17 genes: case-control study among Indian children.
Hypospadias
Metabolism of androstenedione in skin and serum levels of gonadotrophins and androgens in prepubertal boys with hypospadias.
Hypospadias
Molecular diagnosis of 46,XY DSD and identification of a novel 8 nucleotide deletion in exon 1 of the SRD5A2 gene.
Hypospadias
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Hypospadias
Mutation analysis of five candidate genes in Chinese patients with hypospadias.
Hypospadias
Mutation analysis of the SRD5A2, AR and SF-1 genes in 52 Chinese boys with hypospadias.
Hypospadias
Polymorphisms of MAMLD1, SRD5A2, and AR Candidate Genes in Seven Dogs (78,XY; SRY-Positive) Affected by Hypospadias or Cryptorchidism.
Hypospadias
Prenatal exposure to di-n-butyl phthalate (DBP) differentially alters androgen cascade in undeformed versus hypospadiac male rat offspring.
Hypospadias
Screening for mutations in candidate genes for hypospadias.
Hypospadias
Steroid 5-alpha-reductase type 2 (SRD5A2) gene V89L polymorphism and hypospadias risk: A meta-analysis.
Hypospadias
Steroid 5alpha-reductase 1 polymorphisms and testosterone/dihydrotestosterone ratio in male patients with hypospadias.
Hypospadias
The Effect of Intramuscular Testosterone Enanthate Treatment on Stretched Penile Length in Prepubertal Boys With Hypospadias.
Hypospadias
The valine allele of the V89L polymorphism in the 5-alpha-reductase gene confers a reduced risk for hypospadias.
Hypospadias
Urethral development in the fetal rabbit and induction of hypospadias: a model for human development.
Hypospadias
[Identification of mutations of SRD5A2 gene and SRY gene in patients with hypospadias]
Hypospadias
[Karyotyping and analysis of 5? -reductase-2 gene mutation in 25 patients with hypospadias].
Hypospadias
[Mutation analysis of SRD5A2 gene in patients with hypospadias]
Infertility
Differences in testicular development between 5alpha-reductase 2 deficiency and isolated bilateral cryptorchidism.
Infertility, Male
5-Alfa reductase type 2 (SRD5A2) gene rs523349 polymorphism is not associated with non-obstructive azoospermia in Turkish patients.
Insulin Resistance
Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity.
Insulin Resistance
Reduced glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose tissue insulin sensitization after weight loss.
Klinefelter Syndrome
Masculinizing genitoplasty in intersex patients.
Laryngitis
[The effect of hormonal agents on the development of chronic laryngitis and tumor disease. Report of two cases]
Leydig Cell Tumor
Expression of aromatase cytochrome P450 in rat H540 Leydig tumor cells.
Liver Diseases
Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients.
Liver Neoplasms
Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients.
Lordosis
Inhibiting biosynthesis and/or metabolism of progestins in the ventral tegmental area attenuates lordosis of rats in behavioural oestrus.
Lymphatic Metastasis
Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
Lymphatic Metastasis
The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.
Melanoma
Sebocytes are the key regulators of androgen homeostasis in human skin.
Metabolic Syndrome
Single-nucleotide polymorphism in the 5-?-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.
Myoclonus
Estrogen increases latencies to seizures and levels of 5alpha-pregnan-3alpha-ol-20-one in hippocampus of wild-type, but not 5alpha-reductase knockout, mice.
Neoplasm Metastasis
5alpha-reductase 2 polymorphisms as risk factors in prostate cancer.
Neoplasm Metastasis
Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
Neoplasm Metastasis
Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
Neoplasm Metastasis
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Neoplasm Metastasis
Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.
Neoplasm Metastasis
The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.
Neoplasm Metastasis
[Expression of SRD5A1 and its prognostic role in prostate cancer: Analysis based on the data-mining of ONCOMINE].
Neoplasms
'Urology: Today's Advances, Tomorrow's Clinical Practice', Cannes, November 2003. Current thinking in prostatic diseases: insights into dual 5alpha-reductase inhibitor therapy in BPH and prostate cancer.
Neoplasms
5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
Neoplasms
5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.
Neoplasms
A low carbohydrate, high protein diet suppresses intratumoral androgen synthesis and slows castration-resistant prostate tumor growth in mice.
Neoplasms
Adrenal microsomal C19-steroid 5alpha-reductase activity in the Snell transplantable rat adrenocortical tumour 494 and the effect of oestradiol, testosterone propionate and adrenocorticotrophin in intact and gonadectomized rats.
Neoplasms
Androgen Metabolism Gene Polymorphisms, Associations with Prostate Cancer Risk and Pathological Characteristics: A Comparative Analysis between South African and Senegalese Men.
Neoplasms
Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
Neoplasms
Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
Neoplasms
Association of SRD5A2 genotype and pathological characteristics of prostate tumors.
Neoplasms
Associations of polymorphisms in HPC2/ELAC2 and SRD5A2 genes with benign prostate hyperplasia in Turkish men.
Neoplasms
Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study.
Neoplasms
Changes in hepatic steroid metabolism in rat following transplantation of four different clones of pituitary tumor cells.
Neoplasms
Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
Neoplasms
Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis.
Neoplasms
Combined treatment of Dunning R3327 rat prostatic tumor with the 5alpha-reductase inhibitor PNU 157706 and the antiandrogen bicalutamide.
Neoplasms
Conserved effect of aging on DNA methylation and association with EZH2 polycomb protein in mice and humans.
Neoplasms
Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue.
Neoplasms
Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
Neoplasms
Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.
Neoplasms
Dihydrotestosterone concentration in prostate cancer tissue as a predictor of tumor differentiation and hormonal dependency.
Neoplasms
DNA Methyl Transferase 1 Reduces Expression of SRD5A2 in the Aging Adult Prostate.
Neoplasms
DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
Neoplasms
Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats.
Neoplasms
Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Neoplasms
Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
Neoplasms
Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
Neoplasms
Expression of 5alpha-reductases in human epithelial ovarian cancer: its correlation with androgen receptor status.
Neoplasms
Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer.
Neoplasms
Expression of aromatase cytochrome P450 in rat H540 Leydig tumor cells.
Neoplasms
Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma.
Neoplasms
Expression of the insulin-like growth factor (IGF) system and steroidogenic enzymes in canine testis tumors.
Neoplasms
Feminization of hepatic S metabolism in male rats with a transplanted (MtT/F4).
Neoplasms
Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells.
Neoplasms
Gene expression of androgen metabolising enzymes in benign prostatic hyperplasia.
Neoplasms
Genomic analysis of cancer tissue reveals that somatic mutations commonly occur in a specific motif.
Neoplasms
Genotype-phenotype correlation, gonadal malignancy risk, gender preference, and testosterone/dihydrotestosterone ratio in steroid 5-alpha-reductase type 2 deficiency: a multicenter study from Turkey.
Neoplasms
Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
Neoplasms
Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling.
Neoplasms
In situ androgen production in human gastric carcinoma--androgen synthesizing and metabolizing enzymes.
Neoplasms
Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
Neoplasms
Inverse Relationship between Progesterone Receptor and Myc in Endometrial Cancer.
Neoplasms
Involvement of Egr-1 in HGF-induced elevation of the human 5alpha-R1 gene in human hepatocellular carcinoma cells.
Neoplasms
Joint effects of inflammation and androgen metabolism on prostate cancer severity.
Neoplasms
Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer.
Neoplasms
Localization and altered expression of AKR1C family members in human ovarian tissues.
Neoplasms
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Neoplasms
Mammary steroid metabolizing enzymes in relation to hyperplasia and tumorigenesis in the dog.
Neoplasms
Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy.
Neoplasms
Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Neoplasms
Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
Neoplasms
Prevention of prostate-related cancers in Lobund-Wistar rats.
Neoplasms
Prevention, complementary therapies, and new scientific developments in the field of prostate cancer.
Neoplasms
Progesterone metabolism in normal human endometrium during the menstrual cycle and in endometrial carcinoma.
Neoplasms
Promoting effects of antiandrogenic agents on rat ventral prostate carcinogenesis induced by 3,2'-dimethyl-4-aminobiphenyl (DMAB).
Neoplasms
Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
Neoplasms
Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling.
Neoplasms
RE: Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Neoplasms
Rising prostate-specific antigen after primary treatment of prostate cancer: sequential hormone manipulation.
Neoplasms
Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.
Neoplasms
Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5alpha-reductase during prostate cancer progression.
Neoplasms
Some new approaches to potential test systems for drugs against prostatic cancer.
Neoplasms
Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts.
Neoplasms
The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
Neoplasms
The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model.
Neoplasms
The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.
Neoplasms
The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.
Neoplasms
The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
Neoplasms
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.
Neoplasms
Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
Neoplasms
Understanding the epidemiology, natural history, and key pathways involved in prostate cancer.
Neoplasms
Words of wisdom. Re: Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 clinical practice guideline. Kramer BS, Hagerty KL, Justman S, et al.
Neoplasms
[Expression of type I and type II 5alpha-reductase isoenzymes in prostate cancer tissues]
Neuroinflammatory Diseases
Treatment of male rats with finasteride, an inhibitor of 5alpha-reductase enzyme, induces long-lasting effects on depressive-like behavior, hippocampal neurogenesis, neuroinflammation and gut microbiota composition.
Obesity
Activation of the hypothalamic-pituitary-adrenal axis in obesity: cause or consequence?
Obesity, Abdominal
Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver.
Oligospermia
Steroid 5alpha-reductase 2 gene melting polymorphisms in male subjects with azoospermia or oligospermia.
Ovarian Neoplasms
Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set.
Ovarian Neoplasms
Consortium analysis of 7 candidate SNPs for ovarian cancer.
Ovarian Neoplasms
Ovarian cancer survival and polymorphisms in hormone and DNA repair pathway genes.
Ovarian Neoplasms
The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.
Ovotesticular Disorders of Sex Development
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Paget Disease, Extramammary
Androgen receptor and 5alpha-reductase immunohistochemical profiles in extramammary Paget disease.
Parkinson Disease
Comparative non-radioactive RT-PCR assay: an approach to study the neurosteroids biosynthetic pathway in humans.
Peripheral Arterial Disease
ICAM-1 and SRD5A1 gene polymorphisms in symptomatic peripheral artery disease.
Phimosis
Expression of Xenobiotic Biomarkers CYP1 Family in Preputial Tissue of Patients with Hypospadias and Phimosis and Its Association with DNA Methylation Level of SRD5A2 Minimal Promoter.
Phimosis
Stable maintenance of 5alpha-reductase activity in long-term subcultures of fibroblasts derived from the foreskin.
Placental Insufficiency
Changes in 5alpha-pregnane steroids and neurosteroidogenic enzyme expression in fetal sheep with umbilicoplacental embolization.
Polycystic Ovary Syndrome
5alpha-reductase activity in women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Association of genetic variants in the two isoforms of 5?-reductase, SRD5A1 and SRD5A2, in lean patients with polycystic ovary syndrome.
Polycystic Ovary Syndrome
In silico and functional studies reveal novel loss-of-function variants of SRD5A2, but no variants explaining excess 5?-reductase activity.
Polycystic Ovary Syndrome
Increased 5alpha-reductase and normal 11beta-hydroxysteroid dehydrogenase metabolism of C19 and C21 steroids in a young population with polycystic ovarian syndrome.
Polycystic Ovary Syndrome
The 5alpha-reductase type 1, but not type 2, gene is expressed in anagen hairs plucked from the vertex area of the scalp of hirsute women and normal individuals.
Polycystic Ovary Syndrome
Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women.
Porphyria, Acute Intermittent
Induction of a deficiency of steroid delta 4-5 alpha-reductase activity in liver by a porphyrinogenic drug.
Porphyrias
Induction of a deficiency of steroid delta 4-5 alpha-reductase activity in liver by a porphyrinogenic drug.
Prostatic Diseases
'Urology: Today's Advances, Tomorrow's Clinical Practice', Cannes, November 2003. Current thinking in prostatic diseases: insights into dual 5alpha-reductase inhibitor therapy in BPH and prostate cancer.
Prostatic Diseases
5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
Prostatic Diseases
DNA Methyl Transferase 1 Reduces Expression of SRD5A2 in the Aging Adult Prostate.
Prostatic Diseases
Lessons learned about prostatic transformation from the age-related methylation of 5?-reductase type 2 gene.
Prostatic Diseases
The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
Prostatic Hyperplasia
19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
Prostatic Hyperplasia
5alpha-reductase and 17beta-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate.
Prostatic Hyperplasia
5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Prostatic Hyperplasia
5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
Prostatic Hyperplasia
A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH.
Prostatic Hyperplasia
A cost comparison of medical management and transurethral needle ablation for treatment of benign prostatic hyperplasia during a 5-year period.
Prostatic Hyperplasia
A new look at the 5alpha-reductase inhibitor finasteride.
Prostatic Hyperplasia
A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Prostatic Hyperplasia
alpha(1)-Blocker therapy in the nineties: focus on the disease.
Prostatic Hyperplasia
An update on the use of 5alpha-reductase inhibitors.
Prostatic Hyperplasia
Androgen-independent basal cell re-epithelialization, c-erbB-2 mRNA expression and androgen-dependent EGFr mRNA expression in benign prostatic hyperplasia explant cultures treated with finasteride.
Prostatic Hyperplasia
Antimuscarinic therapy in men with lower urinary tract symptoms: what is the evidence?
Prostatic Hyperplasia
Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men.
Prostatic Hyperplasia
Benign prostatic hyperplasia progression and its impact on treatment.
Prostatic Hyperplasia
Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II.
Prostatic Hyperplasia
Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study.
Prostatic Hyperplasia
Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride.
Prostatic Hyperplasia
Cactus flower extracts may prove beneficial in benign prostatic hyperplasia due to inhibition of 5alpha reductase activity, aromatase activity and lipid peroxidation.
Prostatic Hyperplasia
Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study.
Prostatic Hyperplasia
Changes in the Serum Prostatic Biomarkers During the Treatment of Benign Prostatic Hyperplasia with a 5alpha-reductase Inhibitor: Finasteride.
Prostatic Hyperplasia
Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate.
Prostatic Hyperplasia
Clinical Usefulness of Serum Prostate Specific Antigen for the Detection of Prostate Cancer is Preserved in Men Receiving the Dual 5alpha-Reductase Inhibitor Dutasteride.
Prostatic Hyperplasia
Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia.
Prostatic Hyperplasia
Comorbid LUTS and erectile dysfunction: optimizing their management.
Prostatic Hyperplasia
Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride.
Prostatic Hyperplasia
Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
Prostatic Hyperplasia
Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
Prostatic Hyperplasia
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Prostatic Hyperplasia
Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
Prostatic Hyperplasia
Dihydrotestosterone concentration in prostate cancer tissue as a predictor of tumor differentiation and hormonal dependency.
Prostatic Hyperplasia
DNA Methyl Transferase 1 Reduces Expression of SRD5A2 in the Aging Adult Prostate.
Prostatic Hyperplasia
Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite.
Prostatic Hyperplasia
Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells.
Prostatic Hyperplasia
Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
Prostatic Hyperplasia
Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasia.
Prostatic Hyperplasia
Dynamic contrast enhanced magnetic resonance imaging as a biological marker to noninvasively assess the effect of finasteride on prostatic suburethral microcirculation.
Prostatic Hyperplasia
Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study.
Prostatic Hyperplasia
Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia.
Prostatic Hyperplasia
Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy.
Prostatic Hyperplasia
Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.
Prostatic Hyperplasia
Efficacy and tolerability of the dual 5alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men.
Prostatic Hyperplasia
Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility.
Prostatic Hyperplasia
Extracts of Phyllostachys pubescens Leaves Represses Human Steroid 5-Alpha Reductase Type 2 Promoter Activity in BHP-1 Cells and Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia in Rat Model.
Prostatic Hyperplasia
Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells.
Prostatic Hyperplasia
Future concepts in the medical therapy of benign prostatic hyperplasia.
Prostatic Hyperplasia
Genetic polymorphism in sex hormone metabolism and prostate cancer risk.
Prostatic Hyperplasia
Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Prostatic Hyperplasia
Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
Prostatic Hyperplasia
Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.
Prostatic Hyperplasia
In vitro modulation of steroid 5alpha-reductase activity by phospholipases in epithelium and stroma of human benign prostatic hyperplasia.
Prostatic Hyperplasia
Inhibition of human steroid 5beta-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex.
Prostatic Hyperplasia
Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
Prostatic Hyperplasia
Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
Prostatic Hyperplasia
Is there a place for combination medical therapy?
Prostatic Hyperplasia
Isolation and pharmacological characterization of fatty acids from saw palmetto extract.
Prostatic Hyperplasia
Joint effects of inflammation and androgen metabolism on prostate cancer severity.
Prostatic Hyperplasia
Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer.
Prostatic Hyperplasia
Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.
Prostatic Hyperplasia
Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia.
Prostatic Hyperplasia
Longer (TA)n Repeat but not A49T and V89L Polymorphisms in SRD5A2 Gene May Confer Prostate Cancer Risk in South Indian Men.
Prostatic Hyperplasia
Managing benign prostatic hyperplasia.
Prostatic Hyperplasia
Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
Prostatic Hyperplasia
Methyl esters of N-(dicyclohexyl)acetyl-piperidine-4-(benzylidene-4-carboxylic acids) as drugs and prodrugs: a new strategy for dual inhibition of 5 alpha-reductase type 1 and type 2.
Prostatic Hyperplasia
Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
Prostatic Hyperplasia
New innovative therapies for benign prostatic hyperplasia: any advance?
Prostatic Hyperplasia
Pharmacotherapy for nocturia in the elderly patient.
Prostatic Hyperplasia
Phospholipase A2 degradation products modulate epithelial and stromal 5alpha-reductase activity of human benign prostatic hyperplasia in vitro.
Prostatic Hyperplasia
Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications.
Prostatic Hyperplasia
Polymorphisms in the 5alpha reductase type 2 gene and urologic measures of BPH.
Prostatic Hyperplasia
Prevention of benign prostatic hyperplasia disease.
Prostatic Hyperplasia
Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study.
Prostatic Hyperplasia
Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5 .
Prostatic Hyperplasia
Protective effect of Prostane in experimental prostatic hyperplasia in rats.
Prostatic Hyperplasia
Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3.
Prostatic Hyperplasia
Refractory overactive bladder in men: update on novel therapies.
Prostatic Hyperplasia
Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
Prostatic Hyperplasia
Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia.
Prostatic Hyperplasia
Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics.
Prostatic Hyperplasia
Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
Prostatic Hyperplasia
Self organizing molecular field analysis on a series of human 5alpha-reductase inhibitors: Unsaturated 3-carboxysteroid.
Prostatic Hyperplasia
Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer.
Prostatic Hyperplasia
Spermatozoa and chronic treatment with finasteride: a TEM and FISH study.
Prostatic Hyperplasia
SRD5A1 and SRD5A2 are Associated with the Treatment for Benign Prostatic Hyperplasia with the Combination of 5?-reductase Inhibitors and ?-adrenergic-receptor Antagonist.
Prostatic Hyperplasia
SRD5A2 Gene Polymorphisms and the Risk of Benign Prostatic Hyperplasia but not Prostate Cancer.
Prostatic Hyperplasia
Stable expression of human 5alpha-reductase type II in COS1 cells due to chromosomal gene integration: a novel tool for inhibitor identification.
Prostatic Hyperplasia
Steroid 5alpha-reductase inhibitors.
Prostatic Hyperplasia
Structure-activity relationship for inhibition of 5alpha-reductase by triterpenoids isolated from Ganoderma lucidum.
Prostatic Hyperplasia
Testosterone 5?-reductase inhibition by free fatty acids from Sabal serrulata fruits.
Prostatic Hyperplasia
The effect of 5alpha-reductase inhibition with finasteride and dutasteride on bone mineral density in older men with benign prostatic hyperplasia.
Prostatic Hyperplasia
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Prostatic Hyperplasia
The mechanism of epristeride against benign prostatic hyperplasia.
Prostatic Hyperplasia
The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis.
Prostatic Hyperplasia
The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Prostatic Hyperplasia
The role of combination medical therapy in benign prostatic hyperplasia.
Prostatic Hyperplasia
Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR.
Prostatic Hyperplasia
Use of 5alpha-reductase inhibitors to prevent benign prostatic hyperplasia disease.
Prostatic Hyperplasia
Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: a reflection from MTOPS.
Prostatic Hyperplasia
Z-350, a novel compound with alpha 1-adrenoceptor antagonistic and steroid 5 alpha-reductase inhibitory actions: pharmacological properties in vivo.
Prostatic Hyperplasia
[Drug therapy for benign prostatic hyperplasia. Systematic overview]
Prostatic Hyperplasia
[Dutasteride--an inhibitor of 5alpha-reductase of type I and II--in the treatment of patients with prostatic adenoma. What is the latest news?]
Prostatic Hyperplasia
[Efficacy and safety of combined treatment of prostatic adenoma with 5-alpha reductase and alpha-adrenoblockers]
Prostatic Hyperplasia
[Expression and significance of steroid 5alpha-reductase isoenzymes in benign hyperplastic prostate tissues]
Prostatic Hyperplasia
[Medical combination therapy in LUTS suggestive of BPH.]
Prostatic Hyperplasia
[Modern pharmacotherapy of benign prostatic hyperplasia]
Prostatic Intraepithelial Neoplasia
Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
Prostatic Intraepithelial Neoplasia
Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
Prostatic Intraepithelial Neoplasia
Understanding the epidemiology, natural history, and key pathways involved in prostate cancer.
Prostatic Neoplasms
'Urology: Today's Advances, Tomorrow's Clinical Practice', Cannes, November 2003. Current thinking in prostatic diseases: insights into dual 5alpha-reductase inhibitor therapy in BPH and prostate cancer.
Prostatic Neoplasms
19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
Prostatic Neoplasms
5alpha-reductase 2 polymorphisms as risk factors in prostate cancer.
Prostatic Neoplasms
5alpha-reductase and 17beta-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate.
Prostatic Neoplasms
5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Prostatic Neoplasms
5alpha-reductase isozymes and androgen actions in the prostate.
Prostatic Neoplasms
5alpha-reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3.
Prostatic Neoplasms
5alpha-Reductase Isozymes in the Prostate.
Prostatic Neoplasms
5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
Prostatic Neoplasms
5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.
Prostatic Neoplasms
A preliminary investigation of the enzymatic inhibition of 5alpha-reduction and growth of prostatic carcinoma cell line LNCap-FGC by natural astaxanthin and Saw Palmetto lipid extract in vitro.
Prostatic Neoplasms
A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase.
Prostatic Neoplasms
A review of phase III clinical trials of prostate cancer chemoprevention.
Prostatic Neoplasms
Agents in development for prostate cancer prevention.
Prostatic Neoplasms
Allelic frequencies of six polymorphic markers for risk of prostate cancer.
Prostatic Neoplasms
Androgen antagonists: Potential role in prostate cancer prevention.
Prostatic Neoplasms
Androgen Metabolism Gene Polymorphisms, Associations with Prostate Cancer Risk and Pathological Characteristics: A Comparative Analysis between South African and Senegalese Men.
Prostatic Neoplasms
Androgen metabolism genes in prostate cancer health disparities.
Prostatic Neoplasms
Anti-androgenic activity of fatty acids.
Prostatic Neoplasms
Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Prostatic Neoplasms
Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.
Prostatic Neoplasms
Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA.
Prostatic Neoplasms
Association of Polymorphisms in the VDR, CYP17 and SRD5A2 Genes and Prostate Cancer Among Lebanese Men
Prostatic Neoplasms
Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
Prostatic Neoplasms
Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
Prostatic Neoplasms
Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Prostatic Neoplasms
Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II.
Prostatic Neoplasms
Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study.
Prostatic Neoplasms
Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride.
Prostatic Neoplasms
Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
Prostatic Neoplasms
Chemoprevention of prostate cancer with finasteride.
Prostatic Neoplasms
Chemoprevention of prostate cancer.
Prostatic Neoplasms
Chemoprevention of prostate cancer: agents and study designs.
Prostatic Neoplasms
Chemoprevention using dutasteride: the REDUCE trial.
Prostatic Neoplasms
Chemopreventive trials in urologic cancer.
Prostatic Neoplasms
Chemotherapeutic prevention studies of prostate cancer.
Prostatic Neoplasms
Clinical Usefulness of Serum Prostate Specific Antigen for the Detection of Prostate Cancer is Preserved in Men Receiving the Dual 5alpha-Reductase Inhibitor Dutasteride.
Prostatic Neoplasms
Combinatorial androgen receptor targeted therapy for prostate cancer.
Prostatic Neoplasms
Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis.
Prostatic Neoplasms
Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer.
Prostatic Neoplasms
Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.
Prostatic Neoplasms
Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
Prostatic Neoplasms
Current drug therapy for prostate cancer: an overview.
Prostatic Neoplasms
CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population.
Prostatic Neoplasms
Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma.
Prostatic Neoplasms
Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
Prostatic Neoplasms
Determination of sulfates of androsterone and epiandrosterone in human serum using isotope diluted liquid chromatography-electrospray ionization-mass spectrometry.
Prostatic Neoplasms
Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
Prostatic Neoplasms
Differential but Concerted Expression of HSD17B2, HSD17B3, SHBG and SRD5A1 Testosterone Tetrad Modulate Therapy Response and Susceptibility to Disease Relapse in Patients with Prostate Cancer.
Prostatic Neoplasms
Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.
Prostatic Neoplasms
Dihydrotestosterone concentration in prostate cancer tissue as a predictor of tumor differentiation and hormonal dependency.
Prostatic Neoplasms
Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells.
Prostatic Neoplasms
Dutasteride prior to contrast-enhanced colour Doppler ultrasound prostate biopsy increases prostate cancer detection.
Prostatic Neoplasms
Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Prostatic Neoplasms
Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
Prostatic Neoplasms
Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats.
Prostatic Neoplasms
Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Prostatic Neoplasms
Effect of the dual 5alpha-reductase inhibitor PNU 157706 on the growth of dunning R3327 prostatic carcinoma in the rat.
Prostatic Neoplasms
Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells.
Prostatic Neoplasms
Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
Prostatic Neoplasms
Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer.
Prostatic Neoplasms
Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
Prostatic Neoplasms
Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.
Prostatic Neoplasms
Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
Prostatic Neoplasms
Evidence for an association between the SRD5A2 (type II steroid 5 alpha-reductase) locus and prostate cancer in Italian patients.
Prostatic Neoplasms
Factors controlling the expression of 5alpha-reductase in human prostate: A possible new approach for the treatment of prostate cancer.
Prostatic Neoplasms
Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line.
Prostatic Neoplasms
Finasteride.
Prostatic Neoplasms
Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor.
Prostatic Neoplasms
GEN GEN: the genomic genetic analysis of androgen-metabolic genes and prostate cancer as a paradigm for the dissection of complex phenotypes.
Prostatic Neoplasms
Genetic polymorphism in sex hormone metabolism and prostate cancer risk.
Prostatic Neoplasms
Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
Prostatic Neoplasms
Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk.
Prostatic Neoplasms
Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
Prostatic Neoplasms
Heterogeneity in genetic susceptibility to prostate cancer.
Prostatic Neoplasms
Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease.
Prostatic Neoplasms
High-grade prostate cancer and finasteride.
Prostatic Neoplasms
Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue.
Prostatic Neoplasms
Importance of 5?-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.
Prostatic Neoplasms
In silico and functional studies reveal novel loss-of-function variants of SRD5A2, but no variants explaining excess 5?-reductase activity.
Prostatic Neoplasms
In situ androgen producing enzymes in human prostate cancer.
Prostatic Neoplasms
Inherited variation in hormone-regulating genes and prostate cancer survival.
Prostatic Neoplasms
Inhibition of 5alpha-reductase in the rat prostate by Cimicifuga racemosa.
Prostatic Neoplasms
Inhibition of rat prostate carcinogenesis by a 5alpha-reductase inhibitor, FK143.
Prostatic Neoplasms
Inverse regulation of DHT synthesis enzymes 5? Reductase Types 1 and 2 by the androgen receptor in prostate cancer.
Prostatic Neoplasms
Joint effects of inflammation and androgen metabolism on prostate cancer severity.
Prostatic Neoplasms
Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
Prostatic Neoplasms
Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer.
Prostatic Neoplasms
Lifestyle determinants of 5alpha-reductase metabolites in older African-American, white, and Asian-American men.
Prostatic Neoplasms
Longer (TA)n Repeat but not A49T and V89L Polymorphisms in SRD5A2 Gene May Confer Prostate Cancer Risk in South Indian Men.
Prostatic Neoplasms
Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
Prostatic Neoplasms
Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
Prostatic Neoplasms
Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy.
Prostatic Neoplasms
New frontiers in androgen biosynthesis and metabolism.
Prostatic Neoplasms
New progesterone derivatives as inhibitors of 5alpha-reductase enzyme and prostate cancer cell growth.
Prostatic Neoplasms
No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.
Prostatic Neoplasms
Pancreaticoduodenal arterial rupture and hemoabdomen in ACI/SegHsd rats with polyarteritis nodosa.
Prostatic Neoplasms
Perspective: prostate cancer susceptibility genes.
Prostatic Neoplasms
Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Prostatic Neoplasms
Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy.
Prostatic Neoplasms
Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
Prostatic Neoplasms
Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
Prostatic Neoplasms
Polymorphism of the SRD5A2 gene and the risk of prostate cancer.
Prostatic Neoplasms
Polymorphisms in androgen metabolism genes AR, CYP1B1, CYP19, and SRD5A2and prostate cancer risk and aggressiveness in Bulgarian patients.
Prostatic Neoplasms
Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians.
Prostatic Neoplasms
Polymorphisms of HPC2/ELAC2 and SRD5A2 (5?-Reductase Type II) Genes in Prostate Cancer.
Prostatic Neoplasms
Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor.
Prostatic Neoplasms
Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue.
Prostatic Neoplasms
Prevalent mutations in prostate cancer.
Prostatic Neoplasms
Preventing diseases of the prostate in the elderly using hormones and nutriceuticals.
Prostatic Neoplasms
Prevention of prostate-related cancers in Lobund-Wistar rats.
Prostatic Neoplasms
Prostate cancer chemoprevention: Current status and future prospects.
Prostatic Neoplasms
Prostate cancer prevention.
Prostatic Neoplasms
Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
Prostatic Neoplasms
Prostate cancer: a serious disease suitable for prevention.
Prostatic Neoplasms
Provocative aspects of androgen genetics.
Prostatic Neoplasms
Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling.
Prostatic Neoplasms
RE: Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Prostatic Neoplasms
Re: The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
Prostatic Neoplasms
Redistribution of androgen receptors in acquired hormone-refractory prostate cancer cells.
Prostatic Neoplasms
Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial.
Prostatic Neoplasms
Regulation of aromatase and 5alpha-reductase by 25-hydroxyvitamin D(3), 1alpha,25-dihydroxyvitamin D(3), dexamethasone and progesterone in prostate cancer cells.
Prostatic Neoplasms
Relationship between SRD5A2 rs9282858 polymorphism and the susceptibility of prostate cancer: A meta-analysis based on 20 publications.
Prostatic Neoplasms
Relationship of Early-Onset Baldness to Prostate Cancer in African-American Men.
Prostatic Neoplasms
Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor.
Prostatic Neoplasms
Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Prostatic Neoplasms
Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population.
Prostatic Neoplasms
Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.
Prostatic Neoplasms
Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH.
Prostatic Neoplasms
Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
Prostatic Neoplasms
Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer.
Prostatic Neoplasms
Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5alpha-reductase during prostate cancer progression.
Prostatic Neoplasms
Some new approaches to potential test systems for drugs against prostatic cancer.
Prostatic Neoplasms
SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
Prostatic Neoplasms
SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
Prostatic Neoplasms
SRD5A2 gene expression inhibits cell migration and invasion in prostate cancer cell line via F-actin reorganization.
Prostatic Neoplasms
SRD5A2 Gene Polymorphisms and the Risk of Benign Prostatic Hyperplasia but not Prostate Cancer.
Prostatic Neoplasms
SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis.
Prostatic Neoplasms
SRD5A2 V89L polymorphism and prostate cancer risk: A meta-analysis.
Prostatic Neoplasms
Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer.
Prostatic Neoplasms
Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis.
Prostatic Neoplasms
Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review.
Prostatic Neoplasms
Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer.
Prostatic Neoplasms
Structure of human steroid 5?-reductase 2 with the anti-androgen drug finasteride.
Prostatic Neoplasms
Systematic meta-analyses of gene-specific genetic association studies in prostate cancer.
Prostatic Neoplasms
Tests for genetic association using family data.
Prostatic Neoplasms
The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
Prostatic Neoplasms
The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer.
Prostatic Neoplasms
The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
Prostatic Neoplasms
The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population.
Prostatic Neoplasms
The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
Prostatic Neoplasms
The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels.
Prostatic Neoplasms
The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
Prostatic Neoplasms
The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer-results from a 4-month pre-radical prostatectomy study.
Prostatic Neoplasms
The influence of finasteride on the development of prostate cancer.
Prostatic Neoplasms
The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.
Prostatic Neoplasms
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.
Prostatic Neoplasms
The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.
Prostatic Neoplasms
The Motion: All Men Over the Age of 50 Should be Encouraged to Take a 5alpha-Reductase Inhibitor to Prevent Prostate Cancer.
Prostatic Neoplasms
The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
Prostatic Neoplasms
The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
Prostatic Neoplasms
The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Prostatic Neoplasms
The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
Prostatic Neoplasms
The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
Prostatic Neoplasms
The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer.
Prostatic Neoplasms
Theaflavin-3,3'-digallate and penta-O-galloyl-beta-D-glucose inhibit rat liver microsomal 5alpha-reductase activity and the expression of androgen receptor in LNCaP prostate cancer cells.
Prostatic Neoplasms
Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
Prostatic Neoplasms
Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.
Prostatic Neoplasms
V89L polymorphism of the 5alpha-reductase Type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk.
Prostatic Neoplasms
V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression.
Prostatic Neoplasms
Validation of the Pitts unified theory of prostate cancer, late-onset hypogonadism and carcinoma: the role of steroid 5alpha-reductase and steroid aromatase.
Prostatic Neoplasms
Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention.
Prostatic Neoplasms
VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men.
Prostatic Neoplasms
Words of wisdom. Re: Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 clinical practice guideline. Kramer BS, Hagerty KL, Justman S, et al.
Prostatic Neoplasms
[Association between A49T polymorphism of SRD5A2 gene and risk of prostate cancer]
Prostatic Neoplasms
[Chemoprevention of prostate cancer. Current status]
Prostatic Neoplasms
[Chemoprevention of prostate cancer]
Prostatic Neoplasms
[Drug therapy for benign prostatic hyperplasia. Systematic overview]
Prostatic Neoplasms
[Expression of SRD5A1 and its prognostic role in prostate cancer: Analysis based on the data-mining of ONCOMINE].
Prostatic Neoplasms
[Expression of type I and type II 5alpha-reductase isoenzymes in prostate cancer tissues]
Prostatic Neoplasms
[Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer]
Prostatic Neoplasms
[Influence of dihydrotestosterone deficit on treatment of prostatic diseases regarding to contemporary methods of prostatic hypertrophy treatments]
Prostatic Neoplasms
[Role of 5alpha-reductase inhibitors in the chemoprevention of prostate cancer].
Prostatic Neoplasms
[V89L polymorphism of the testosterone 5-alpha-reductase II gene and prognostic factors of prostate cancer].
Prostatitis
Experimental autoimmune prostatitis: dihydrotestosterone influence over the immune response.
Prostatitis
The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis.
Seizures
Allopregnanolone, the active metabolite of progesterone protects against neuronal damage in picrotoxin-induced seizure model in mice.
Seizures
Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy.
Seizures
Estrogen increases latencies to seizures and levels of 5alpha-pregnan-3alpha-ol-20-one in hippocampus of wild-type, but not 5alpha-reductase knockout, mice.
Seizures
Finasteride, a 5alpha-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice.
Seizures
Long-term social isolation enhances picrotoxin seizure susceptibility in mice: up-regulatory role of endogenous brain allopregnanolone in GABAergic systems.
Seizures
Progesterone reduces pentylenetetrazol-induced ictal activity of wild-type mice but not those deficient in type I 5alpha-reductase.
Seizures
Seizure activity is increased in endocrine states characterized by decline in endogenous levels of the neurosteroid 3 alpha,5 alpha-THP.
Seizures
Social isolation stress and neuroactive steroids.
Seizures
[Androgens and epilepsy].
Seminoma
Expression of the insulin-like growth factor (IGF) system and steroidogenic enzymes in canine testis tumors.
Sleep Deprivation
Changes in the expression of steroid metabolism-related genes in rat adrenal glands during selective REM sleep deprivation.
Sleep Deprivation
Influence of sleep disturbance on steroid 5alpha-reductase mRNA levels in rat brain.
steroid 11beta-monooxygenase deficiency
Molecular genetics of disorders of sex development in a highly consanguineous population.
Testicular Neoplasms
Single-nucleotide polymorphism in the 5-?-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.
Urinary Bladder Neck Obstruction
Current status of 5alpha-reductase inhibitors in the treatment of benign hyperplasia of prostate.
Urinary Bladder Neck Obstruction
Z-350, a novel compound with alpha 1-adrenoceptor antagonistic and steroid 5 alpha-reductase inhibitory actions: pharmacological properties in vivo.
Urinary Bladder Neck Obstruction
[Clinical and urodynamic evaluation of efficacy of conservative treatment of urination disorders in patients with benign prostate hyperplasia].
Urinary Retention
Benign prostatic hyperplasia progression and its impact on treatment.
Urinary Retention
Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate.
Urinary Retention
Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
Urinary Retention
Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications.
Urinary Retention
Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
Urinary Retention
Noninvasive management of lower urinary tract symptoms and sexual dysfunction associated with benign prostatic hyperplasia in the primary care setting.
Urinary Retention
The role of dihydrotestosterone in benign prostatic hyperplasia.
Urinary Retention
Update on the use of dutasteride in the management of benign prostatic hypertrophy.
Urinary Retention
Urinary retention and post-void residual urine in men: separating truth from tradition.
Urinary Retention
[Pharmacological treatment of benign prostatic hyperplasia.]
Uterine Cervical Neoplasms
Altered urinary profiles of polyamines and endogenous steroids in patients with benign cervical disease and cervical cancer.
Varicose Veins
Elevated sex steroid hormones in great saphenous veins in men.
Wilms Tumor
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Wilms Tumor
New frontiers on the molecular underpinnings of hypospadias according to severity.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0000002
(11aR)-7-(1-hydroxypropan-2-yl)-1,4a,6a-trimethyltetradecahydrocyclopenta[5,6]naphtho[2,1-d][1,3]oxazine-2(1H)-thione
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000062
(16alpha,17beta)-17-hydroxy-16-methylandrost-4-en-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000052
(17beta)-16-ethyl-17-hydroxyandrost-4-en-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000026
(17beta)-17-[di(propan-2-yl)carbamoyl]-4-fluoroandrost-3-ene-3-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000035
(17beta)-17-[di(propan-2-yl)carbamoyl]-4-methylandrosta-3,5-diene-3-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000032
(17beta)-17-[di(propan-2-yl)carbamoyl]-6-fluoroandrosta-3,5-diene-3-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00003
(17beta)-17-[di(propan-2-yl)carbamoyl]androst-3-ene-3-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000007
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-2,4,6-triene-3-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000007
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-3,5,11-triene-3-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000007
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-3,5-diene-3-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00005
(17beta)-17-[di(propan-2-yl)carbamoyl]estra-3,5-diene-3-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000387
(17beta)-4-bromo-N-tert-butyl-3-oxoandrost-4-ene-17-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000437
(17beta)-N-tert-butyl-3-oxo-4-sulfanylandrost-4-ene-17-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000192
(17beta)-N-tert-butyl-4-chloro-3-oxoandrost-4-ene-17-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000029
(17beta)-N-tert-butyl-4-cyano-3-oxoandrost-4-ene-17-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000007
(1R,4R,9aR,11aR)-4,9a,11a-trimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000001
(1R,4S,9aR,11aR)-4,9a,11a-trimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000001
(1R,9aR,11aR)-9a,11a-dimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000034
(1S,8bS,10aS)-N,N-diethyl-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,7,7a,8,8a,8b,8c,9,10,10a-hexadecahydrocyclopenta[i]cyclopropa[a]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000001
(1S,9aR,11aR)-1-butyl-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
Homo sapiens
below, pH not specified in the publication, temperature not specified in the publication
0.0000001
(1S,9aR,11aS)-1-(cyclohexylacetyl)-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
Homo sapiens
below, pH not specified in the publication, temperature not specified in the publication
0.0000001
(1S,9aR,11aS)-6-bromo-9a,11a-dimethyl-7-oxo-N-(tricyclo[3.3.1.13,7]dec-1-yl)-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
below, pH not specified in the publication, temperature not specified in the publication
0.0000021
(1S,9aR,11aS)-6-bromo-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000001
(1S,9aR,11aS)-6-chloro-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
below, pH not specified in the publication, temperature not specified in the publication
0.000009
(1S,9aR,11aS)-6-chloro-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000001
(1S,9aR,11aS)-9a,11a-dimethyl-1-nonanoyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
Homo sapiens
below, pH not specified in the publication, temperature not specified in the publication
0.0000001
(1S,9aR,11aS)-9a,11a-dimethyl-N-(2-methylpropyl)-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
below, pH not specified in the publication, temperature not specified in the publication
0.0000023
(1S,9aR,11aS)-N,N-diethyl-5,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000057
(1S,9aR,11aS)-N,N-diethyl-5,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000039
(1S,9aR,11aS)-N,N-diethyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000015
(1S,9aR,11aS)-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000001
(1S,9aR,11aS)-N-(4,4'-di-tert-butylbiphenyl-3-yl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
below, pH not specified in the publication, temperature not specified in the publication
0.0000001
(1S,9aR,11aS)-N-(4-tert-butylbiphenyl-3-yl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
below, pH not specified in the publication, temperature not specified in the publication
0.0000001
(1S,9aR,11aS)-N-(5-bromo-2-tert-butylphenyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
below, pH not specified in the publication, temperature not specified in the publication
0.0000004
(1S,9aR,11aS)-N-(dicyclohexylmethyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000001
(1S,9aR,11aS)-N-(diphenylmethyl)-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
below, pH not specified in the publication, temperature not specified in the publication
0.0000001
(1S,9aR,11aS)-N-(diphenylmethyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
below, pH not specified in the publication, temperature not specified in the publication
0.0000014
(1S,9aR,11aS)-N-tert-butyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000001
(1S,9aR,11aS)-N-[1-(4-chlorophenyl)cyclobutyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
below, pH not specified in the publication, temperature not specified in the publication
0.0000001
(1S,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
below, pH not specified in the publication, temperature not specified in the publication
0.0000001
(1S,9aR,11aS)-N-[2-tert-butyl-5-(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
below, pH not specified in the publication, temperature not specified in the publication
0.00000012
(1S,9aR,11aS)-N-[bis(4-chlorophenyl)methyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000018
(1S,9aS,11aS)-N,N-diethyl-8,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00058
(20E)-20-(hydroxyimino)pregn-4-en-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0003
(21E)-21-(hydroxyimino)pregn-4-en-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000033
(22R,S)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000005
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (2-fluorophenyl)acetate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000018
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-bromopropanoate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000014
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-chloropropanoate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00001
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-iodopropanoate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000007
(4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]-3-fluorophenyl)acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000006
(4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]phenyl)acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0014
(4aR,10bR)-4,10b-dimethyl-8-[(E)-2-phenylethenyl]-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00001
(4aR,10bR)-8-(furan-2-yl)-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.01
(4aR,10bR)-8-chloro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0013
(4aR,10bR)-8-[(E)-2-(isoquinolin-4-yl)ethenyl]-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000029
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000055
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-4a,6a,10-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000147
(4aR,6aR)-1,4a,6a,10-tetramethyl-7-(6-methylheptan-2-yl)-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000125
(4aR,6aR)-1,4a,6a,10-tetramethyl-7-(6-methylheptan-2-yl)-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000054
(4aR,6aR)-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)-10-propyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000218
(4aR,6aR)-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)hexadecahydro-2H-indeno[5,4-f]quinolin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00033
(4aR,6aR)-10-ethyl-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)hexadecahydro-2H-indeno[5,4-f]quinolin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000298
(4aR,6aR)-4a,6a,10-trimethyl-7-(6-methylheptan-2-yl)-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000014
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-2-oxo-N-(4,4,4-trifluoro-2-methyl-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000016
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-2-oxo-N-(4,4,4-trifluoro-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000008
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-N-(2-methyl-4-oxopentan-3-yl)-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000262
(4aR,6aS,11aR)-N-(2-cyanopropan-2-yl)-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00021
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000011
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-phenylhexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000007
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-[2-(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000002
(4aR,6aS,7S)-4a,6a-dimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000015
(4aR,6aS,7S)-4a,6a-dimethyl-2,5-dioxo-N-phenylhexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00005
(4aR,6aS,7S)-N,1,4a,6a-tetramethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00002
(4aR,6aS,7S)-N,4a,6a-trimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00001
(4aR,6aS,7S)-N-(2-chlorophenyl)-1,4a,6a-trimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00002
(4aR,6aS,7S)-N-[2,5-bis(trifluoromethyl)phenyl]-1,4a,6a-trimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.001553
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000381
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000154
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-2-oxo-N-(4,4,4-trifluoro-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.001218
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000055
(4aR,6aS,7S,11aR)-N-(3,3-dimethylpentanoyl)-1,4a,6a-trimethyl-N-(2-methylbutan-2-yl)-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000001
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-1,4a,6a-trimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000016
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000001
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
below, pH not specified in the publication, temperature not specified in the publication
0.000212
(4aR,6aS,7S,11aR)-N-cyclohexyl-N-(cyclohexylacetyl)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000005
(4aR,6aS,7S,11aR)-N-[2,5-bis(trifluoromethyl)phenyl]-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000019
(4aS,6aS,7S,11aR)-4a,6a-dimethyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[5,4-f]isoquinolin-7-ol
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000004
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N,N-diphenyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000246
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N-phenyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000001
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N-[2-(trifluoromethyl)phenyl]-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
Homo sapiens
below, pH not specified in the publication, temperature not specified in the publication
0.0000252
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-7-[methyl(phenyl)carbamoyl]-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinolinium
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000001
(4aS,6aS,7S,11aS)-N,N-di(1H-indol-1-yl)-4a,6a-dimethyl-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000002
(4aS,6aS,7S,11aS)-N-(biphenyl-3-yl)-4a,6a-dimethyl-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
Homo sapiens
below, pH not specified in the publication, temperature not specified in the publication
0.000003
(5alpha17beta)-17-N,N-diethylcarbamoyl-4-methyl-4-aza-5-androstan-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000174
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethyl-1,2,3,3a,3b,4,5,5a,6,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000036
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethylhexadecahydro-7H-indolo[5,4-f]quinolin-7-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000103
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-9a,11a-dimethyl-1,2,3,3a,3b,4,5,5a,6,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000401
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-9a,11a-dimethylhexadecahydro-7H-indolo[5,4-f]quinolin-7-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.012
(6aR,7S,9aR,11aS)-7-hydroxy-1,9a,11a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.015
(6aS,10aS,12aS)-1,10a,12a-trimethylhexadecahydronaphtho[2,1-f]quinoline-2,8-dione
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.004
(6aS,8S,10aS,12aS)-8-hydroxy-1,10a,12a-trimethylhexadecahydronaphtho[2,1-f]quinolin-2(1H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000318
(7aR,9aS,10S)-N,N-diethyl-7a,9a-dimethyl-5-oxo-1,2,3,5,6,7,7a,7b,8,9,9a,10,11,12,12a,12b-hexadecahydrobenzo[b]indeno[5,4-d]azepine-10-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.002
(7aS,8S,12aR)-7a-methyl-8-(phenylamino)-5a,6,7,7a,8,9,10,10a,10b,11,12,12a-dodecahydrocyclopenta[f]pyrido[1,2-a]quinolin-2(1H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000247
(7aS,8S,12aR)-8-[benzyl(phenyl)amino]-7a-methyl-5a,6,7,7a,8,9,10,10a,10b,11,12,12a-dodecahydrocyclopenta[f]pyrido[1,2-a]quinolin-2(1H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00046
(8a,9b,10x,14x)-N-tert-butyl-3-oxoestr-4-ene-17-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.04
(8R,9aS,11aS)-1,9a,11a-trimethyl-2-oxo-N,N-di(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-8-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000052
(9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethyl-1,2,3,3a,3b,4,6,8,9,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000046
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]-butyric acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000046
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]butyric acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000005
1-cyclopropyl-3-methyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000023
1-cyclopropyl-3-phenyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000617
1-methyl-5-[4-[(E)-2-phenylethenyl]phenyl]piperidin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000579
1-methyl-5-[4-[(E)-phenyldiazenyl]phenyl]piperidin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000019
17beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5alpha-androstan-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000041
17beta-N-(2,5-bis(trifluoromethyl)-phenyl)-3-oxo-4-aza-5alpha-androst-1-ene-17-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000582
2-methyl-N-phenyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]propanamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00001
3-chloro-4-(4-[N-(4-phenoxybenzyl)amino]phenoxy)benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000073
3-chloro-4-([1-(4-phenoxybenzoyl)-1H-indol-5-yl]oxy)benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000053
3-chloro-4-([1-(4-phenoxybenzyl)indolin-5-yl]oxy)benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000032
3-cyclohexyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000071
4'-[2-[di(propan-2-yl)amino]-2-oxoethoxy]-3',5'-di(propan-2-yl)biphenyl-4-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000098
4'-[2-[di(propan-2-yl)amino]-2-oxoethoxy]-3'-fluoro-5'-nitrobiphenyl-4-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0063
4-(3-[[2,2-bis(4-chlorophenyl)-1,3-benzodioxol-5-yl]carbonyl]-2-methyl-1H-indol-1-yl)butanoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000005
4-(4-benzoylphenoxy)benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000087
4-(biphenyl-4-yloxy)-2-chlorobenzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000067
4-(biphenyl-4-yloxy)-2-fluorobenzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000056
4-(biphenyl-4-yloxy)-3-methoxybenzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00005
4-cyanoprogesterone
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000021
4-[(1-benzyl-1H-indol-5-yl)oxy]-3-chlorobenzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00034
4-[2-(6-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000004
4-[3-(4-[(1R)-1-[4-(2-methylpropyl)phenyl]ethoxy]benzoyl)-1H-indol-1-yl]butanoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000023
4-[3-([(2R)-2-methyl-2-[4-(2-methylpropyl)phenyl]-1,3-benzodioxol-5-yl]carbonyl)-1H-indol-1-yl]butanoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000019
4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]-lH-indol-l-yl]butyric acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00001
4-[4-(4-methylbenzoyl)phenoxy]benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00038
4-[4-(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)phenoxy]benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000011
4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]-3-fluorobenzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000006
5-(2-ethyl-3-[3-[(4-hexylundecyl)amino]benzoyl]-1H-pyrrol-1-yl)pentanoate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0123
5-(4-chlorophenyl)-1-methylpiperidin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.001
5-bromo-N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]pentanamide
Homo sapiens
about, pH not specified in the publication, temperature not specified in the publication
0.0000037
6,20-dioxopregn-4-en-3-yl 4-fluorobenzoate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000003
6,20-dioxopregna-4,16-dien-3-yl 4-fluorobenzoate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000004
6,20-dioxopregna-4,16-dien-3-yl 4-methylbenzoate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000033
6-bromo-3,20-dioxopregna-4,6-dien-17-yl acetate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00075
6-[3-(N,N-dicyclohexylaminocarbonyl)phenyl]-3,4-dihydro-naphthalene-2-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0002
6-[4-(N,N-diisopropylamino-carbonyl)phenyl]naphthalene-2-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00034
7-[(E)-2-phenylethenyl]-9,10-dihydrophenanthrene-2-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00003
epristeride
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0046
estra-4,9(11)-diene-3,17-dione
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000003
finasteride
Homo sapiens
type II 5alpha-reductase, pH not specified in the publication, temperature not specified in the publication
0.0000032
methyl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000018
N-(1,1,1,3,3,3-hexafluorophenylpropyl)-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0001
N-(3,3-dimethylbutyl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
above, pH not specified in the publication, temperature not specified in the publication
0.0000022
N-(3-methylbutan-2-yl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0001
N-(3-methylbutyl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
above, pH not specified in the publication, temperature not specified in the publication
0.001
N-(4-methoxycyclohexyl)-2-methyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]propanamide
Homo sapiens
about, pH not specified in the publication, temperature not specified in the publication
0.0000026
N-butyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000014
N-heptyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000184
N-octyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000018
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.001
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]butanamide
Homo sapiens
about, pH not specified in the publication, temperature not specified in the publication
0.0001
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
above, pH not specified in the publication, temperature not specified in the publication
0.0000038
N-phenyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]benzamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000051
N-propyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0001
N-propyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
above, pH not specified in the publication, temperature not specified in the publication
0.000051
N-[1,1,1-trifluoro-2-oxobut-3-yl]-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000001 - 0.00000016
tricyclo[3.3.1.13,7]dec-2-yl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
0.000005
[3-methyl-4-(4-phenoxybenzoyl)phenyl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000023
[4-(4-phenoxybenzoyl)phenyl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00006
[4-(biphenyl-4-yloxy)phenyl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000027
[4-[4-(4-bromophenoxy)benzoyl]phenyl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000377
(10bR)-8-chloro-4,10b-dimethyl-1,4,6,10b-tetrahydrobenzo[f]quinoline-3(2H)-thione
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000062
(16alpha,17beta)-17-hydroxy-16-methylandrost-4-en-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000000063
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000000079
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl butanoate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000032
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl pentanoate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000012
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl phenylacetate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00000052
(17beta)-16-ethyl-17-hydroxyandrost-4-en-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00027
(17beta)-17-(2-oxo-3-phenyl-1,3-oxazinan-6-yl)androst-4-en-3-one
Homo sapiens
-
37°C
0.0005
(17beta)-17-[3-(4-bromophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
Homo sapiens
-
37°C
0.00042
(17beta)-17-[3-(4-chlorophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
Homo sapiens
-
37°C
0.000245
(17beta)-17-[3-(4-ethoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
Homo sapiens
-
37°C
0.00026
(17beta)-17-[3-(4-ethylphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
Homo sapiens
-
37°C
0.0006
(17beta)-17-[3-(4-methoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
Homo sapiens
-
37°C
0.000026
(17beta)-17-[di(propan-2-yl)carbamoyl]-4-fluoroandrost-3-ene-3-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000035
(17beta)-17-[di(propan-2-yl)carbamoyl]-4-methylandrosta-3,5-diene-3-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000032
(17beta)-17-[di(propan-2-yl)carbamoyl]-6-fluoroandrosta-3,5-diene-3-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00003
(17beta)-17-[di(propan-2-yl)carbamoyl]androst-3-ene-3-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000007
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-2,4,6-triene-3-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000007
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-3,5,11-triene-3-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000007
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-3,5-diene-3-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00005
(17beta)-17-[di(propan-2-yl)carbamoyl]estra-3,5-diene-3-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000981
(17beta)-4-bromo-N-tert-butyl-3-oxoandrost-4-ene-17-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000709
(17beta)-N-tert-butyl-3-oxo-4-sulfanylandrost-4-ene-17-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.001
(17beta)-N-tert-butyl-4-chloro-3-oxoandrost-4-ene-17-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000079
(1R,4R,9aR,11aR)-4,9a,11a-trimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000012
(1R,4S,9aR,11aR)-4,9a,11a-trimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000023
(1R,9aR,11aR)-9a,11a-dimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000035
(1S,8bS,10aS)-N,N-diethyl-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,7,7a,8,8a,8b,8c,9,10,10a-hexadecahydrocyclopenta[i]cyclopropa[a]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000012
(1S,9aR,11aR)-1-butyl-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000004
(1S,9aR,11aS)-1-(cyclohexylacetyl)-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000045
(1S,9aR,11aS)-6-bromo-9a,11a-dimethyl-7-oxo-N-(tricyclo[3.3.1.13,7]dec-1-yl)-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000097
(1S,9aR,11aS)-6-bromo-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000006
(1S,9aR,11aS)-6-chloro-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000051
(1S,9aR,11aS)-6-chloro-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000001
(1S,9aR,11aS)-9a,11a-dimethyl-1-nonanoyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000009
(1S,9aR,11aS)-9a,11a-dimethyl-N-(2-methylpropyl)-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00018
(1S,9aR,11aS)-N,N-diethyl-5,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000013
(1S,9aR,11aS)-N,N-diethyl-5,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00004
(1S,9aR,11aS)-N,N-diethyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00075
(1S,9aR,11aS)-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000013
(1S,9aR,11aS)-N-(4,4'-di-tert-butylbiphenyl-3-yl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000046
(1S,9aR,11aS)-N-(4-tert-butylbiphenyl-3-yl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000042
(1S,9aR,11aS)-N-(5-bromo-2-tert-butylphenyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00002
(1S,9aR,11aS)-N-(dicyclohexylmethyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000036
(1S,9aR,11aS)-N-(diphenylmethyl)-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00003
(1S,9aR,11aS)-N-(diphenylmethyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000012
(1S,9aR,11aS)-N-tert-butyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000068
(1S,9aR,11aS)-N-[1-(4-chlorophenyl)cyclobutyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000004
(1S,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000088
(1S,9aR,11aS)-N-[2-tert-butyl-5-(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00002
(1S,9aR,11aS)-N-[bis(4-chlorophenyl)methyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000014
(1S,9aS,11aS)-N,N-diethyl-8,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00163
(20E)-20-(hydroxyimino)pregn-4-en-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00195
(21E)-21-(hydroxyimino)pregn-4-en-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000036
(22R,S)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000005 - 0.000005
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (2-fluorophenyl)acetate
0.0000007
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (3-fluorophenyl)acetate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00031
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl phenylacetate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000018
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-bromopropanoate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000014
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-chloropropanoate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00001
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-iodopropanoate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000049
(4alpha,5alpha)-3,20-dioxo-4,5-epoxypregnan-17-yl 4-bromobenzoate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000013
(4alpha,5alpha)-3,20-dioxo-4,5-epoxypregnan-17-yl benzoate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000006
(4aR,10bR)-4,10b-dimethyl-8-[(E)-2-phenylethenyl]-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000011
(4aR,10bR)-4,8-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000059
(4aR,10bR)-8-(furan-2-yl)-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000035
(4aR,10bR)-8-bromo-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00006
(4aR,10bR)-8-chloro-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000017
(4aR,10bR)-8-chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000183
(4aR,10bR)-8-chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinoline-3(2H)-thione
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000008
(4aR,10bR)-8-chloro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000035
(4aR,10bR)-8-fluoro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000006
(4aR,10bR)-8-[(E)-2-(isoquinolin-4-yl)ethenyl]-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000029
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000055
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-4a,6a,10-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000006
(4aR,6aR)-1,4a,6a,10-tetramethyl-7-(6-methylheptan-2-yl)-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000002
(4aR,6aR)-1,4a,6a,10-tetramethyl-7-(6-methylheptan-2-yl)-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000084
(4aR,6aR)-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)-10-propyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000017
(4aR,6aR)-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)hexadecahydro-2H-indeno[5,4-f]quinolin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000057
(4aR,6aR)-10-ethyl-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)hexadecahydro-2H-indeno[5,4-f]quinolin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000016
(4aR,6aR)-4a,6a,10-trimethyl-7-(6-methylheptan-2-yl)-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000014
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-2-oxo-N-(4,4,4-trifluoro-2-methyl-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000016
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-2-oxo-N-(4,4,4-trifluoro-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000008
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-N-(2-methyl-4-oxopentan-3-yl)-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000262
(4aR,6aS,11aR)-N-(2-cyanopropan-2-yl)-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00003
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000005
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-phenylhexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000002
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-[2-(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000013
(4aR,6aS,7S)-4a,6a-dimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00041
(4aR,6aS,7S)-4a,6a-dimethyl-2,5-dioxo-N-phenylhexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00012
(4aR,6aS,7S)-N,1,4a,6a-tetramethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00042
(4aR,6aS,7S)-N,4a,6a-trimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000006
(4aR,6aS,7S)-N-(2-chlorophenyl)-1,4a,6a-trimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000006
(4aR,6aS,7S)-N-[2,5-bis(trifluoromethyl)phenyl]-1,4a,6a-trimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.001218
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000055
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000009
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-2-oxo-N-(4,4,4-trifluoro-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.001553
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000381
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000212
(4aR,6aS,7S,11aR)-N-(3,3-dimethylpentanoyl)-1,4a,6a-trimethyl-N-(2-methylbutan-2-yl)-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000001
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-1,4a,6a-trimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000016
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000001
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000041
(4aR,6aS,7S,11aR)-N-cyclohexyl-N-(cyclohexylacetyl)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000081
(4aR,6aS,7S,11aR)-N-[2,5-bis(trifluoromethyl)phenyl]-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.001
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N,N-diphenyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00002
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N-phenyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000056
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N-[2-(trifluoromethyl)phenyl]-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00035
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-7-[methyl(phenyl)carbamoyl]-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinolinium
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00012
(4aS,6aS,7S,11aS)-N,N-di(1H-indol-1-yl)-4a,6a-dimethyl-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000014
(4aS,6aS,7S,11aS)-N-(biphenyl-3-yl)-4a,6a-dimethyl-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000000063
(5alpha,6alpha)-20-oxo-5,6-epoxypregn-16-en-3-yl acetate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000017
(5alpha17beta)-17-N,N-diethylcarbamoyl-4-methyl-4-aza-5-androstan-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000477
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethyl-1,2,3,3a,3b,4,5,5a,6,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000765
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-9a,11a-dimethyl-1,2,3,3a,3b,4,5,5a,6,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0022
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-9a,11a-dimethylhexadecahydro-7H-indolo[5,4-f]quinolin-7-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.012
(6aR,7S,9aR,11aS)-7-hydroxy-1,9a,11a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.015
(6aS,10aS,12aS)-1,10a,12a-trimethylhexadecahydronaphtho[2,1-f]quinoline-2,8-dione
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.004
(6aS,8S,10aS,12aS)-8-hydroxy-1,10a,12a-trimethylhexadecahydronaphtho[2,1-f]quinolin-2(1H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000318
(7aR,9aS,10S)-N,N-diethyl-7a,9a-dimethyl-5-oxo-1,2,3,5,6,7,7a,7b,8,9,9a,10,11,12,12a,12b-hexadecahydrobenzo[b]indeno[5,4-d]azepine-10-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000279
(7aS,8S,12aR)-7a-methyl-8-(phenylamino)-5a,6,7,7a,8,9,10,10a,10b,11,12,12a-dodecahydrocyclopenta[f]pyrido[1,2-a]quinolin-2(1H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000913
(7aS,8S,12aR)-8-[benzyl(phenyl)amino]-7a-methyl-5a,6,7,7a,8,9,10,10a,10b,11,12,12a-dodecahydrocyclopenta[f]pyrido[1,2-a]quinolin-2(1H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.001134
(8a,9b,10x,14x)-N-tert-butyl-3-oxoestr-4-ene-17-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.04
(8R,9aS,11aS)-1,9a,11a-trimethyl-2-oxo-N,N-di(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-8-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.007
(9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethyl-1,2,3,3a,3b,4,6,8,9,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000046
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]-butyric acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000046
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]butyric acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0065
1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000273
1-cyclopropyl-3-ethyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000005
1-cyclopropyl-3-methyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000023
1-cyclopropyl-3-phenyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000013 - 0.0000115
1-cyclopropyl-3-phenyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
0.002477
1-methyl-5-phenylpiperidin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000107
1-methyl-5-[4-[(E)-2-phenylethenyl]phenyl]piperidin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000302
1-methyl-5-[4-[(E)-phenyldiazenyl]phenyl]piperidin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00011
17-hydroxypregna-4,6-diene-3,20-dione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0003
17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000017
17beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5alpha-androstan-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000024
17beta-N-(2,5-bis(trifluoromethyl)-phenyl)-3-oxo-4-aza-5alpha-androst-1-ene-17-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000105
2-methyl-N-phenyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]propanamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00049
2-oxo-8-(prop-2-en-1-yl)-2H-chromen-7-yl benzoate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00005
3,20-dioxopregna-4,6-dien-17-yl (4-bromophenyl)carbamate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000031 - 0.00037
3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
0.00009
3,20-dioxopregna-4,6-dien-17-yl 4-chlorobenzoate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000026
3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000063 - 0.00036
3,20-dioxopregna-4,6-dien-17-yl benzoate
0.00001
3,20-dioxopregna-4,6-dien-17-yl phenylcarbamate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000242
3-butyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000053
3-butyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00001
3-chloro-4-(4-[N-(4-phenoxybenzyl)amino]phenoxy)benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000073
3-chloro-4-([1-(4-phenoxybenzoyl)-1H-indol-5-yl]oxy)benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000053
3-chloro-4-([1-(4-phenoxybenzyl)indolin-5-yl]oxy)benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000032
3-cyclohexyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000315
3-cyclohexyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00513
4,4a,5,6,7,8,9,10-octahydro-3H-pyrido[1,2-a]quinolin-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00002 - 0.000137
4,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
0.000067
4-(1-benzyl-1H-indol-5-yl)benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00084
4-(3-(4-(N-methylacetamido)phenyl) pentan-3-yl) phenyldibenzylcarbamate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00001
4-(3-[[2,2-bis(4-chlorophenyl)-1,3-benzodioxol-5-yl]carbonyl]-2-methyl-1H-indol-1-yl)butanoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000005
4-(4-benzoylphenoxy)benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000087
4-(biphenyl-4-yloxy)-2-chlorobenzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000067
4-(biphenyl-4-yloxy)-2-fluorobenzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000056
4-(biphenyl-4-yloxy)-3-methoxybenzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00005
4-cyanoprogesterone
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000021
4-[(1-benzyl-1H-indol-5-yl)oxy]-3-chlorobenzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00005
4-[2-(6-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00004
4-[3-(4-[(1R)-1-[4-(2-methylpropyl)phenyl]ethoxy]benzoyl)-1H-indol-1-yl]butanoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000025
4-[3-([(2R)-2-methyl-2-[4-(2-methylpropyl)phenyl]-1,3-benzodioxol-5-yl]carbonyl)-1H-indol-1-yl]butanoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000019
4-[3-[3-[bis (4-isobutylphenyl)methyl amino] benzoyl]-lH-indol-l-yl] butyric acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00001
4-[4-(4-methylbenzoyl)phenoxy]benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00038
4-[4-(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)phenoxy]benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000006
5-(2-ethyl-3-[3-[(4-hexylundecyl)amino]benzoyl]-1H-pyrrol-1-yl)pentanoate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00169
5-(4-chlorophenyl)-1-methylpiperidin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00336
5-(4-chlorophenyl)-1-methylpiperidine-2-thione
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000242
5-bromo-N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]pentanamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000037
6,20-dioxopregn-4-en-3-yl 4-fluorobenzoate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000018
6,20-dioxopregna-4,16-dien-3-yl 3-bromopropanoate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000014
6,20-dioxopregna-4,16-dien-3-yl 3-chloropropanoate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00001
6,20-dioxopregna-4,16-dien-3-yl 3-iodopropanoate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000003
6,20-dioxopregna-4,16-dien-3-yl 4-fluorobenzoate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000004
6,20-dioxopregna-4,16-dien-3-yl 4-methylbenzoate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000000065
6,20-dioxopregna-4,16-dien-3-yl acetate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00000007
6,20-dioxopregna-4,16-dien-3-yl benzoate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000143
6,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000033
6-bromo-3,20-dioxopregna-4,6-dien-17-yl acetate
0.00097
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00099
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-chlorobenzoate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00093
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00092
6-chloro-3,20-dioxopregna-4,6-dien-17-yl benzoate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00081
6-[3-(N,N-dicyclohexylaminocarbonyl)phenyl]-3,4-dihydro-naphthalene-2-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00068
6-[4-[di(propan-2-yl)carbamoyl]phenyl]-3,4-dihydronaphthalene-2-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0013
7-[(3-methylbut-2-en-1-yl)oxy]-2H-chromen-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000152
7-[(E)-2-phenylethenyl]-9,10-dihydrophenanthrene-2-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00099
8-allyl-7-hydroxycoumarin
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00006
8-bromo-4-methyl-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.02
8-chloro-1,2,5,6,6a,7,8,9,10,10a-decahydro-3H-pyrido[1,2-a]quinolin-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000058
8-chloro-1,2,5,6,7,8,9,10-octahydro-3H-pyrido[1,2-a]quinolin-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000049
8-chloro-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00046
8-chloro-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000204
8-chloro-1-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000459
8-chloro-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000085
8-chloro-4,6-dimethyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00003
8-chloro-4-methyl-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000076
8-chloro-4-methyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000176
8-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00003
epristeride
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000055 - 0.0003
finasteride
0.00015
methyl(1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000039
N-(1,1,1,3,3,3-hexafluorophenylpropyl)-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000235
N-(3,3-dimethylbutyl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000022
N-(3-methylbutan-2-yl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000219
N-(3-methylbutyl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000544
N-(4-methoxycyclohexyl)-2-methyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]propanamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000026
N-butyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000957
N-heptyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000169
N-octyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000018
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000177
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]butanamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000091
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000293
N-phenyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]benzamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000051
N-propyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000305
N-propyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000051
N-[1,1,1-trifluoro-2-oxobut-3-yl]-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00000085
pregna-4,16-diene-3,6,20-trione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000069 - 0.00002
tricyclo[3.3.1.13,7]dec-2-yl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
0.00006
[4-(biphenyl-4-yloxy)phenyl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000001
tricyclo[3.3.1.13,7]dec-2-yl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
Homo sapiens
below, pH not specified in the publication, temperature not specified in the publication
0.00000016
tricyclo[3.3.1.13,7]dec-2-yl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000005
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (2-fluorophenyl)acetate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000005
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (2-fluorophenyl)acetate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000013
1-cyclopropyl-3-phenyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000115
1-cyclopropyl-3-phenyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000031
3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00037
3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000063
3,20-dioxopregna-4,6-dien-17-yl benzoate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00036
3,20-dioxopregna-4,6-dien-17-yl benzoate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00002
4,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000137
4,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000033
6-bromo-3,20-dioxopregna-4,6-dien-17-yl acetate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000033
6-bromo-3,20-dioxopregna-4,6-dien-17-yl acetate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000055
finasteride
Homo sapiens
-
37°C
0.0003
finasteride
Homo sapiens
type I 5alpha-reductase, pH not specified in the publication, temperature not specified in the publication
0.0000069
tricyclo[3.3.1.13,7]dec-2-yl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00002
tricyclo[3.3.1.13,7]dec-2-yl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.